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Abstract 
 
Chemotherapy frequently fails to cure cancer patients due to toxicity or resistance 
to treatment. Variability in toxicity and resistance is influenced by polymorphisms 
and mutations in the individual's genome (Pharmacogenetics). Zebrafish has 
extensive evolutionary conservation with human, its genetics is a powerful gene 
discovery tool, and it has been described as a suitable model in cancer research. To 
study chemotherapy resistance, we used ENU-mutagenised zebrafish in a forward 
genetic screen to identify genes that modify responses to cancer chemotherapy. 
Zebrafish larvae were challenged with two chemotherapeutic drugs and stained 
with acridine orange (AO) to detect apoptosis and reveal hypo- or hyper-responders 
to chemotherapy.  
A mutation, conferring an increased uptake of AO, was identified by genetic 
mapping as a premature stop codon truncating the ribonuclease T2 (rnaset2) gene. 
Human RNASET2 encodes a putative lysosomal RNase. Lysosomal storage 
disorders, due to deficiencies in lysosomal hydrolases and resultant accumulation 
of macromolecules within lysosomes, are collectively among the commonest 
genetic diseases. RNASET2 deficiency in man results in a static encephalopathy 
arising in infancy and characterized by multifocal bilateral white matter lesions, 
subcortical cysts and focal enlargement of the anterior inferior horn.  
This doctoral thesis demonstrates that rnaset2 deficient zebrafish embryos suffer 
from a lysosomal storage disorder accumulating undigested ribosomal RNA 
(rRNA) in enlarged lysosomes within neurons of the brain. Moreover, high-field 
intensity µMRI revealed white matter lesions in the brain of adult rnase2 mutant 
animals. Thus, this zebrafish mutant can be used as a model to study the 
abnormalities observed in RNASET2 deficient individuals. This model suggests 
that the leukoencephalopathy results from a lysosomal storage disorder and 
provides a preclinical model for further elaborating disease mechanisms and 
evaluating candidate therapeutics. 
RNASET2 has also been advanced as a candidate tumour suppressor in several 
solid tumours. Recombinant rnaset2 protein has been tested in the clinic as an anti-
cancer cytotoxic agent, with anti-angiogenic properties. By combining the rnaset2 
mutant presented here with a transgenic melanoma model developed in the 
laboratory, the tumour suppressor and angiogenic role for rnaset2 was refuted.  
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Chapter I: Introduction 
. 
1.1 Cancer and Chemotherapy 
1.1.1 Cancer 
Cancer is caused by the malfunction, the absence of function or up-regulated 
function of certain genes, which can be classified into three main categories: DNA 
repair genes, tumour suppressor genes and oncogenes. Cancer is initiated by DNA 
mutation and during this initiation, several outcomes can occur such as DNA repair 
or removal of damaged cells by apoptosis. These responses can reverse the 
initiation, but if a mutation persists, the proliferation of abnormal cells, called 
mutant clones, can lead to disease progression and formation of a benign tumour. 
Without spontaneous regression or surgical removal, benign tumours may become 
malignant and metastatic (Loktionov 2004). 
 
The phenotype of all cancers can be categorized according to six fundamental 
physiological properties that are responsible for malignant growth (Figure 1.1) 
(Hanahan and Weinberg 2000): 
 
1. Self-sufficiency in growth signals 
2. Insensitivity to growth-inhibitory signals 
3. Evasion of apoptosis 
4. Limitless replicative potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis 
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Cancer is not a single disease and because of complications with treatments such as 
resistance and severe side effects, an effective cure is not yet available. However 
chemotherapy is still the best way to treat disseminated diseases. 
 
 
Figure 1.1: Acquired capabilities of cancer (Hanahan and Weinberg 2000) 
 
1.1.2 Chemotherapy 
Chemotherapy is the mainstay of treatment for metastatic and haematological 
malignancies. Since the 40’s, when crude cytotoxic agents were used, such as 
nitrogen mustard, chemotherapy has increased its specificity and decreased its 
toxicity by using chemically diverse new drugs, including both natural products 
(plant-derived alkaloids and cytotoxic antibiotics) and purely synthetic compounds 
(alkylating agents, carboplatins)(Steel and Costanzo 2003). 
Paul Ehrlich (winner of the Nobel prize in medicine in 1908) defined the concept 
of chemotherapy: “a chemical will have a selectively toxic effect if a target is 
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uniquely expressed in a particular cell type and if enough of the active drug or 
toxin interacts with it to perturb cellular metabolism” (Hickman 1996). 
Cancer treatments available today are not as selective as Paul Ehrlich described, 
but their objective is to kill cancer cells. Chemotherapeutic drugs can be used under 
different regimes as described below. Cancer drugs induce cell death by three main 
modes of cytotoxicity i) damage to chromosomal DNA, ii) inactivation of enzymes 
in growth-promoting pathways and iii) disruption of the mitotic spindle (Gottesman 
2002). These three modes of cytotoxity induce damage to cancer cells and result in 
cell death mainly via apoptosis. Many chemotherapeutic drugs are available with 
different cellular targets. 
1.1.2.1 Types of chemotherapy 
 
There are different modalities of chemotherapy, each one having a different goal. 
Curative chemotherapy is applied to patients who can survive only with this 
treatment and not with surgery or radiotherapy. The chemotherapy constitutes then 
the major therapeutic intervention that could potentially cure the patient. Very 
often this curative chemotherapy entails clinical risk and may even induce toxicity. 
This treatment is used for fatal cancers such as leukaemia, lymphomas, testicular 
and ovarian cancer, bone sarcomas and neuroblastomas (Steel and Costanzo 2003). 
Adjuvant chemotherapy is used after surgery or radiotherapy; it is not necessary for 
cure and typically it is of benefit for only 10% of patients. Adjuvant therapy may 
harm or even kill patients who did not require it, which results in an ethical 
dilemma about the use of this kind of cancer treatment. Non-tolerant chemotherapy 
patients should not be treated because of the adverse effects. 
Palliative chemotherapy is very often used for terminal cancers such as chronic 
myeloid leukaemia, chronic lymphoid leukaemia, myeloma, metastatic breast 
cancer, thyroid cancer. The main goal is to improve the comfort of patients (Archer 
V.R. 1999). 
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1.1.2.2 Cellular targets 
 
In cancer chemotherapy, the ultimate goal is to induce death in cancer cells and 
different cellular targets are used to attack cancer cells such as: DNA, the mitotic 
spindle and enzymes. 
Damage to chromosomal DNA can be performed either through covalent cross-
linking (e.g. Cisplatin), intercalation (e.g. the anthracyclines), or otherwise 
interfering with DNA metabolism (e.g. the topoisomerase inhibitor camptothecin) 
or DNA synthesis (eg: anti-metabolite drug methotrexate). The aim is to damage 
the DNA to either activate the DNA damage repair system or disrupt replication 
and /or transcription resulting in apoptosis (Zhou and Elledge 2000). 
The microtubule cytoskeleton is required to maintain cell shape, for cell division 
and for intracellular transport (Jordan and Wilson 2004). Taxanes (Paclitaxel and 
Docetaxel) and vinca alkaloids (Vinblastine and Vincristine) are microtubule 
disrupting agents used in chemotherapy (Steel and Costanzo 2003). The main 
target of these drugs is the spindle which segregates chromosomes in mitosis. 
Inhibiting enzymes involved in growth pathways is also a target used in cancer 
treatment. Oncogene inhibition or tumour suppressor gene activation constitutes 
another way to inhibit tumour growth. Activity of phosphatases or kinases 
responsible for oncogene activation can be inhibited by specific small inhibitor 
molecules. As an example, in chronic myelogenous leukemia (CML) patients, the 
Philadelphia translocation creates a Bcr-Abl oncoprotein with enhanced protein 
tyrosine kinase (PTK) activity (Bartram, de Klein et al. 1983; Heisterkamp, 
Stephenson et al. 1983). Imatinib was developed as a PTK inhibitor through 
binding to the active site of the Abl-kinase (Buchdunger, Zimmermann et al. 
1996). It produced dramatic results in clinical trials for CML patients and is now 
used as an effective treatment in clinics (Druker, Guilhot et al. 2006). 
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1.1.2.3 Cell death 
 
Depending on the stimulus, a cell can die through different mechanisms: necrosis, 
apoptosis or autophagy. 
Necrosis can be considered a “dirty” way to die; indeed death by necrosis does not 
go unnoticed. Cells undergo necrosis after high mechanical or temperature stress 
and show swelling of organelles, disruption of the cytoplasmic membrane and 
consequently cell lysis (Majno and Joris 1995). This damage activates the immune 
response and the wound healing response that will clear the cell debris (Zong and 
Thompson 2006). Cancers often display chronic necrosis and constant 
inflammation associated with poor prognosis as the persistent inflammation has 
been shown to promote tumour growth and metastasis (Balkwill 2004). It is 
therefore essential to avoid inducing necrosis during chemotherapy treatment. 
Apoptosis is a form of programmed cell death that plays an important role in the 
removal of cells that are in excess or potentially dangerous. This term was adopted 
in 1972 when researchers identified a form of cell death morphologically different 
from necrosis and conserved in various cell types and tissues (Kerr, Wyllie et al. 
1972). The caspase family of proteins are the main cellular effectors of apoptosis: 
once activated, they cleave cellular substrates, resulting in the appearance of 
characteristic apoptosis features, such as i) chromatin condensation and nuclear 
fragmentation, ii) contraction and membrane blebbing and iii) cell size reduction 
(Kerr, Wyllie et al. 1972). Two different pathways can induce apoptosis: the 
intrinsic pathway controlled by Bcl-2 proteins and involving the mitochondria, and 
the extrinsic pathway regulated by the membrane receptor tumour necrosis factor 
(TNF) family (Hengartner 2000). Cancer cells often inhibit pro-apoptotic genes (eg 
p53, Bax) and activate anti-apoptotic proteins (eg Bcl-2, Akt) to evade apoptosis 
(Jaattela 2004). It was found that in the case of complete inhibition of apoptosis, 
cell death can still occur through lysosomal enzymes. The lysosomal cell death 
pathway acts by releasing the lysosomal hydrolase cathepsins which can then 
execute apoptosis (Kirkegaard and Jaattela 2009). 
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Autophagy is a cellular degradation pathway induced by starvation or stress, where 
molecules, organelles and cytoplasm are engulfed in double membrane vesicles. 
They will then become autophagosomes by fusion to lysosomes that will digest and 
recycle their content to the extra-cellular matrix to sustain cellular balance (Levine 
and Klionsky 2004; Mizushima 2007). Autophagy also acts as a homeostatic 
pathway, maintaining organelle and protein quality control, it can also eliminate 
pathogens and apoptotic cells (Colombo 2007; Qu, Zou et al. 2007). Autophagy 
has a role in tumour suppression, some essential genes for autophagy, such as 
ATG6 and ATG4, were found mutated in some cancers and deficient mice are 
prone to develop tumours (Liang, Jackson et al. 1999; Qu, Yu et al. 2003; Marino, 
Salvador-Montoliu et al. 2007). In contradiction, autophagy also helps tumour cells 
to survive in metabolic stress condition in hypoxic regions (Degenhardt, Mathew et 
al. 2006). These controversial results pushed researchers to further study the role of 
autophagy in cancer. 
Apoptosis is crucial to suppress tumourigenesis. Around one hundred 
chemotherapeutic drugs are available, which are all very efficient at inducing cell 
death in culture conditions. However, in vivo efficacy may be less impressive. 
Unfortunately cancer cells acquire drug resistance to most treatments and 
ultimately, chemotherapy fails the majority of cancer sufferers. Tumour cells re-
emerge that are resistant to the cytotoxic effects of the drugs. This mechanism is 
called chemoresistance and in most cases, the underlying causes are multifactorial 
and frequently obscure (Gottesman, Fojo et al. 2002). 
1.1.3. Chemotherapy resistance 
Resistance can be innate in some cell populations prior to treatment and/or specific 
to a single entity (e.g. mutation of the reduced folate carrier renders cells resistant 
to the antifolate methotrexate)(Guo, Healey et al. 1999). But it can also be acquired 
during a long term exposure to one or several chemotherapeutic drugs; in this latter 
case it is called Multi Drug Resistance (MDR), implying that tumours have 
undergone alterations in pathways common to the metabolism or action of many 
drugs. All cancer cells have a different genetic make up and every tumour exhibits 
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huge heterogeneity in the expression of genes conferring resistance to 
chemotherapy. This array of resistant genes expressed by tumours combined to a 
potent selection imposed by a cancer drug can result in rapid growth of resistant 
clones and emergence of MDR after treatment (Gottesman 2002). 
Because of drug resistance, single drug chemotherapy failed to deliver a long term 
clinical response. However, combination therapy was tested and appeared as a 
good model for cancer treatment; it combined drugs with different mechanisms of 
action and different toxicities, sometimes with synergy between two drug families 
to increase the therapeutic index. For example, Paclitaxel combined with 
Epirubicin showed a better and longer efficiency to treat ovarian cancer (Ray-
Coquard, Bachelot et al. 2003). Chemotherapy can also be combined with 
radiotherapy, the alkylating agent temozolomide admistered before and after 
radiotherapy showed improvement in the treatment of glioma (Stupp, Mason et al. 
2005). However, pharmacogenetics and pharmacogenomics offer tools to predict a 
patient response to chemotherapy, this new field combining genomics and 
proteomics can identify biomarkers responsible for resistance. These technologies 
can be used to identify tumours likely to respond to a given chemotherapy and 
provide adapted individual therapy. 
1.2 Polymorphisms and drug responses 
1.2.1 Pharmacogenetics and Pharmacogenomics 
Pre 1950s, physicians took into account age, gender, renal function, nutritional 
status, liver function, disease aetiology, and drug interactions when prescribing 
medicines. Post 1950s, scientists began acquiring new knowledge about drug 
metabolism, drug disposition, target/receptor mechanisms, and genetic 
polymorphisms. Alongside this, inter-individual differences in drug responses were 
starting to be documented for some treatments. Researchers observed striking 
differences from different patients in response to standard treatment. This variation 
of clinical phenotype led to the identification of the protein involved with the 
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responsible polymorphisms (Weinshilboum 2003). In 1954, Hughes et al., working 
on the secondary effects of Isoniazid— a drug first created to treat tuberculosis— 
found that variations in the gene coding for the enzyme acetylating Isoniazid was 
responsible for the peripheral neuropathy observed in a subset of patients (Hughes, 
Biehl et al. 1954). Since then, in vivo studies based on inherited individual 
variation of drug response were called pharmacogenetics. This focuses on patient 
variability, testing one compound against many patient genomes. The aim is to 
give a specific treatment for a group of patients expressing the same genetic 
pattern. This new field allowed people to consider the concept of an individualised 
therapy that could revolutionise medicine (Lindpainter 2002). Alongside 
pharmacogenetics, pharmacogenomics examine (in vitro and in vivo) the effect of 
drugs and their metabolites on the expression of genes involved in drug 
metabolism. The focus is on drugs, regarding the gene-expression response to 
several compounds. All together, this new field was called pharmacogenetics and 
is summarised in figure 1.2 (Roden, Altman et al. 2006). 
 
The uncontrolled secondary effects to drugs represent 1 in 16 hospital admissions 
in the UK (Pirmohamed, James et al. 2004) and £380 million a year to treat these 
patients (Marsh and McLeod 2006) . It is the 6th ranking cause of mortality 
globally and the first ranking reason for emergency admission in the USA 
(epipath.net). It also represents a considerable problem for pharmaceutical 
industries with the small amount of drugs being commercialised due to 
cytotoxicity. The goal of pharmacogenetics is to help pharmaceutical research and 
development, improving the selection of patients prior to drug treatment to avoid 
resistance and toxicity (Figure 1.3). Pharmacogenetics therefore emerged as a new 
hope to improve the efficacy and safety of modern medicine. To understand how 
gene variations can modulate the effect of the drug on its target, it is essential to 
first comprehend how an agent can reach its target, in order words the 
pharmacokinetics of the drug. 
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Figure 1.2: The concept of pharmacogenetics (Roden, Altman et al. 2006) 
 
 
 
 
 
 
 
 
Figure 1.3: The objectives of pharmacogenetics. Pharmacogenetics will identify 
patients at risk for toxicity or resistance prior to drug treatment 
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1.2.2 Drug pharmacokinetics 
 
Pharmacokinetics (PK) describes the Absorption, Distribution, Metabolism, and 
Excretion (ADME) of a drug (Lindpainter 2002). To reach its cellular target, drugs 
must first be absorbed by the organism, perhaps transformed, and then distributed 
to its target(s). Drugs pharmacokinetics can be divided into two different parts: the 
first being the passage of drugs across various membranes (absorption, distribution 
and excretion). And the second described as metabolism, when drugs are modified 
by metabolic enzymes. 
From the administration until the target location, compounds need to pass through 
different membranes. Administration can be made orally, by respiratory tracts or 
intravenously. Oral and respiratory treatment are less efficient and slower than 
other routes because of the convoluted path the drug has to take to reach its target, 
whereas intravenous administration has a complete and rapid bioavailability 
(Undevia, Gomez-Abuin et al. 2005). Absorption and excretion use different 
transport modes: passive diffusion, facilitated diffusion, active transport I and II, 
and endocytosis. The distribution is via blood circulation to aqueous or lipid parts 
of the organism, called extra-vascular space, where some drugs can become 
inactive after binding to plasma proteins. 
The ADME step with the biggest impact on drug action is metabolism. Metabolism 
is a natural protection for the body and its role is to remove xenobiotics as quickly 
as possible. Water-soluble products are easily eliminated while lipophilic 
compounds must be transformed first. Two classes of enzymes are responsible for 
drug transformations: 
- Phase I enzymes modify the drug (oxidation, reduction or hydrolysis). This 
functionalisation phase is mainly carried out by the cytochrome P450 enzyme 
(CYP) family, 57 different members are present in human (Lewis 2004). The 
CYP1, CYP2 and CYP3 are implicated commonly in drug and other xenobiotic 
metabolism (Rendic and Di Carlo 1997). After phase I, the majority of drugs are 
pharmacologically inactive because of the loss of their reactive function and 
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became prodrugs. A prodrug is a “pharmacologically inactive derivative of an 
active drug that must undergo metabolic conversion to the active agent”(Undevia, 
Gomez-Abuin et al. 2005). The prodrug needs to undergo the second phase in 
metabolism. 
- Phase II enzymes add an endogenous agent to the modified drug; it is called the 
conjugation phase. In this reaction the drug is conjugated to endogenous moieties 
to become water-soluble and allow elimination. This conjugation is achieved by 
several metabolic enzymes such as: glutathione S-transferases (GSTs), UDP-
glucuronosyltransferases (UDP-GTs), N-acetyltransferases (NATs), and 
methyltransferases. 
1.2.3 Polymorphisms modifying drug responses 
Pharmacogenetics identified polymorphisms in genes responsible for resistance, 
affecting drug action at different levels (Table 1.1)(Longley and Johnston 2005): 
-Drug inactivation/ metabolism: inactivation of drugs can decrease the binding to 
their cellular targets. Metabolism defects can modify the drug ADME and therefore 
reduce its action (see 1.2.2). 
-Drug absorption, influx/ efflux: enhancement of drug efflux by ATP-dependent 
ABC-transporters can modify the drug absorption. 
-DNA damage repair: Cancer cells can bypass DNA damage repair mechanisms 
and escape apoptosis. 
-Drug targets: mutation or alteration in drug targets can have a major impact on 
drug resistance 
-Regulation of apoptosis: as described in 1.1.2.3, apoptosis is the main targeted 
pathway for chemotherapy. Mutation in apoptotic regulator genes will have a 
dramatic effect on chemotherapy efficacy. 
Cancer pathogenesis and chemotherapy are strongly affected by these polymorphic 
genes (Loktionov 2004). A long list of various polymorphisms in proteins 
modifying anticancer-drug activity is already available in the literature (Table 1.1). 
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To reinforce the advantages of pharmacogenetics in cancer research, some 
examples from clinical application are essential. 
The thiopurine S-methyltransferase (TPMT) is a famous pharmacogenetics 
example. TPMT is a phase I metabolic enzyme that catalyses methylation of 6-
mercaptopurine (6-MP) and thioguanine, two chemotherapy agents used in Acute 
Lymphoblastic Leukemia (ALL)(Remy 1963; Lennard 1992). Its polymorphism 
has been studied in 1980 with a group of volunteers: 21 polymorphisms were 
found for TPMT, three of those being responsible for low or no enzyme activity 
(Salavaggione, Wang et al. 2005). Without TPMT, 6-MP cannot be eliminated 
properly; patients were then “overdosed” and showed severe hematopoietic 
toxicity (Lennard and Lilleyman 1989). In some patients with ALL, TMPT 
deficiency was shown to provoke second malignancies such as brain tumours 
(Relling, Rubnitz et al. 1999). This identification brought the clinicians to a 
molecular prognostic before treatment and TPMT pharmacogenetics has become 
today a commercially available test for ALL patients (Wang and Weinshilboum 
2006) 
The glutathione S-transferase (GST) is a phase II metabolic enzyme that 
conjugates glutathione to drugs. GSTM1 and GSTT1 are two different GSTs and 
respectively ~50% and ~25% of the population have homozygous deletions for 
these enzymes (Hayes and Strange 2000). Various polymorphisms were discovered 
in the GST genes and were found to confer resistance to many chemotherapy 
agents (Petros and Evans 2004). Moreover, GSTT1 deletion can also increase 
toxicity and decrease survival in patient with acute myeloid leukemia (Davies, 
Robison et al. 2001). 
Another famous case of pharmacogenetics that went into the clinics was the 
story about the poly (ADP-Ribose) polymerase (PARP), an enzyme involved in 
base excision repair (Hoeijmakers 2001). Mutations in BRCA genes (BReast 
CAncer susceptibility), which are responsible for DNA double-strand break 
damage repair, were shown to increase susceptibility to breast cancer (Tutt and 
Ashworth 2002; Wooster and Weber 2003). PARP inhibitors were designed but 
never showed a tremendous effect in clinics until the inhibitor Olaparib (Tentori 
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and Graziani 2005). Alan Ashworth’s laboratory discovered that, in BRCA1 and 
BRCA2 deficient background, there was increased sensitivity to PARP inhibition 
with Olaparib (Farmer, McCabe et al. 2005). The inhibition of PARP combined 
with BRCA deficiency lead to an accumulation of DNA strand-breaks without 
functional enzymes able to repair the lesions. Olaparib is now in phase III clinical 
trial for BRCA deficient breast cancer patients (Fong, Boss et al. 2009). 
Altogether, the interpretation of these studies shows how differently 
polymorphisms can affect chemotherapy, and the importance to adapt the treatment 
to each patient individually. 
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Protein function Protein or Gene Drug affected Reference 
 CYP2B6 cyclophosphamine 
(Xie, Yasar et al. 
2003) 
    
 CYP2C8 paclitaxel (Dai, Zeldin et al. 2001) 
Drug 
inactivation/ 
metabolism 
GSHa cisplatin, carboplatin, 
oxaliplatin (Kelland 1993) 
 DPDa 5-fluorouracil (5-FU) (Takebe, Zhao et 
al. 2001) 
 UGT1A1a irinotecan (Cummings, Boyd et al. 2002) 
 MDR1 
vincristine, vinblastine, 
doxorubicine, 
daunorubicin, taxol 
(Ramachandra, 
Ambudkar et al. 
1998) 
Drug influx/ 
efflux MRP1, MRP2 multiple 
(Savas, Cole et al. 
1992) 
    
 RFC methotrexate, tomudex (Bertino 1993) 
 ERCC1a protein cisplatin (Youn, Kim et al. 2004) 
DNA damage 
repair    
 
mismatch repair 
MLH1 cisplatin 
(Brown, Hirst et 
al. 1997) 
 
Topoisomerase 
I campothecin 
(Li, Haluska et al. 
1996) 
Drug targets    
 
Topoisomerase 
II 
doxorubicine, 
etoposide 
(Jordan and 
Wilson 2004) 
 BCL2 multiple (Miyashita and Reed 1992) 
Regulation of 
apoptosis    
 p53 multiple (Pietsch, Humbey 
et al. 2006) 
 
Table 1.1: Examples of resistance mechanisms due to polymorphisms. 
aAbbreviations used: DPD: dihydropyrimidine dehydrogenase, GSH: Thiol 
glutathione, UGT1A1: diphosphogluronyl transferase 1A1, ERCC1: Excision 
repair cross-complementing 1. 
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1.2.4 Pharmacogenetics of vincristine and camptothecin 
Vincristine (Vn) was extracted from Vinca rosea, a plant native of Madagascar. 
This drug belongs to the Vinca alkaloid family including other drugs such as: 
Vinblastine, Vindesine, Vinorelbine, which are all spindle poisons. They 
destabilise and suppress microtubule polymerization resulting in spindle disruption, 
which lead to mitosis defects and ultimately to apoptosis (Jordan and Wilson 
2004). 
Vn is used in treatment of many human cancers such as: acute leukaemia, 
Hodgkin’s disease, non-Hodgkin’s lymphoma, neuroblastomas, cancers of the 
colon, rectum, brain, breast, cervix, head and neck, ovary, lung and thyroid. This 
drug is metabolised by the liver and the major toxicities are haematological, 
gastrointestinal, dermatological, hepatic, neurological (neuropathy), pulmonary and 
ocular (Steel and Costanzo 2003). 
Some polymorphisms have measurable effects on vincristine toxicity, such as 
mutations in MDR1 and CYP3A5 (mainly responsible for Vn elimination). 
However, none of the effects of these polymorphisms were confirmed in vivo in 
ALL patients (Moore and Pinkerton 2009). 
 
Camptothecin (CT), also called Irinotecan, is a topoisomerase I (Topo-I) inhibitor. 
This enzyme relaxes super-coiled DNA inducing nicks in the double strand to 
facilitate replication. CT is used against Topo-I by stabilizing the complex between 
the enzyme and the nicked 3’-phosphate end of the DNA strand. The formation of 
this complex induces irreversible double strand breaks leading to apoptosis 
(D'Arpa and Liu 1989). 
CT is also used in cancer treatment, especially for colorectal cancer, carcinoma of 
the lung, ovary, and other malignancies. This drug treatment can cause different 
toxicities, such as haematological, gastrointestinal, dermatological, hepatic, 
neurological and pulmonary problems (Steel and Costanzo 2003). 
CT is susceptible to polymorphisms in metabolic enzymes. Its main transformation 
is into SN-38 (7-ethyl-10-hydroxycamptothecin), which is more potent than CT 
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itself (Kawato, Aonuma et al. 1991). Polymorphism in the phase II enzyme 
UGT1A, which catalyses glucuronide conjugation to form inactive SN-38 
glucuronide (SN-38G), results in decreased expression and low activity, and 
colorectal patients with high ratio SN-38/SN-38G showed severe cytotoxicity 
(Beutler, Gelbart et al. 1998; Marcuello, Altes et al. 2004). MDR1 is involved in 
pumping out SN-38; polymorphisms have been show to significantly increase 
exposure to the drug and also result in cytotoxicity (Sugiyama, Kato et al. 1998; 
Mathijssen, Marsh et al. 2003). And of course, polymorphisms down regulating 
Topo-I gene expression have been shown to induce resistance to CT treatment in 
human cells (Desai, Li et al. 2001; Morandi, Zingaretti et al. 2006). 
 
1.3 Zebrafish as a model organism 
1.3.1 Zebrafish (Danio Rerio) 
After the long work of George Streisinger to prove the capacity of zebrafish to be a 
new genetic system, it appears now to be a leader among model organisms for 
biomedical research (Grunwald and Eisen 2002). Since the first international 
conference in 1990 focused on this organism, researchers have employed zebrafish 
to study development, behaviour, genetics, pharmacology and even drug discovery 
(Langheinrich 2003). Zebrafish come from the tropical waters of northern India 
and have the advantage of developing ex utero transparent embryos. 
Embryogenesis is completed by 4 day post fertilisation (dpf) and the optical clarity 
allows inspection of internal organs without the necessity of dissection. These 
properties were exploited by Charles Kimmel who worked on cell fate during 
embryogenesis; his work revealed remarkable similarities with mammalian 
development (Kimmel, Warga et al. 1990). 
The mouse was the first vertebrate used for large scale screens to study 
phenotypical traits or metabolic defects, but the intrauterine mode of 
embryogenesis made the study in the early stages of development difficult 
(McDonald, Bode et al. 1990). Zebrafish, with its ex-utero embryonic development 
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and its translucent embryo, appeared as a perfect model for genetic screens. These 
findings lead to the “Big Screen” that identified thousands of zebrafish mutants 
with developmental defects: two large genetic screens were carried out 
simultaneously in Europe and in the United States, all mutants were phenotypically 
characterised and provided a huge platform for future analysis in identifying genes 
regulating vertebrate development (Driever, Solnica-Krezel et al. 1996; Haffter, 
Granato et al. 1996). 
Zebrafish was soon appreciated as a vertebrate model providing physiological and 
morphological complexity of mammalian systems whilst also sharing the high-
throughput qualities attributed to cell culture and invertebrate systems such as i) 
small size combined with simple, cheap and space efficient aquaculture allow large 
numbers of zebrafish to be maintained in the laboratory environment, ii) large 
number of offspring: a mating pair can produce between 100-200 embryos at a 
time, iii) Short generation time: sexually mature within 3-4 months, iv) small size: 
adult zebrafish are 2 centimetres long (Figure 1.4)(Goldsmith 2004). 
 
1.3.2 Zebrafish as a model to study diseases 
Researchers nowadays can benefit from a wide range of tools, information and 
experience to use zebrafish as a model system. The zebrafish genome sequence is 
close to completion with the latest release of zv8 whole genome assembly showing 
striking conservation with the human genome (www.ensembl.org/Danio_rerio/). A 
variety of refined molecular, genetic and imaging techniques are available to use in 
zebrafish. 
Zebrafish had already proved its worth in large-scale genetic screens exposing the 
ability of zebrafish to be used in mutagenesis (Driever, Solnica-Krezel et al. 1996; 
Haffter, Granato et al. 1996). N-ethyl-N-nitrosourea (ENU) was shown to be the 
most efficient mutagenic agent to induce recoverable point mutations throughout 
the whole zebrafish genome compared to X-rays (Mullins, Hammerschmidt et al. 
1994). ENU is a DNA alkylating agent, particularly at the O6 position of guanine 
and O4 position of thymine (Knapik, Goodman et al. 1998). Insertional 
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mutagenesis can also be used for mutagenesis, using a retrovirus insertion library 
(Amsterdam, Nissen et al. 2004). Unlike ENU, retrovirus insertion is not as 
efficient in mutagenesis, but it offers a precious advantage when it comes to 
recover the mutation. The retrovirus insertions can be easily cloned, sequenced and 
located, whereas ENU mutations are recovered by a long and laborious positional 
cloning (Amsterdam and Hopkins 2006). 
Chemical and insertional mutagenesis are so far the best techniques to mutagenise 
the zebrafish genome. New technologies are arising, such as transposons with the 
Sleeping Beauty and Tol 2 system (Kawakami, Shima et al. 2000). Zinc finger 
nucleases system also succeeded to introduce specific mutation into the zebrafish 
genome (Woods and Schier 2008). 
To assess the loss of a specific gene directly, several reverse genetic tools are 
available. Morpholinos (MOs) represent the most used technique to knock down 
genes; however, their effect is transient, lasting only during the first few days of 
development (Nasevicius and Ekker 2000). RNAi (RNA interference) knock down 
using the CMV (cytomegalovirus) promoter to deliver high level expression of 
shRNA (short hairpin RNA) also showed knock down in the exogenous green 
fluorescent protein (GFP) and the endogenous no tail gene (Su, Zhu et al. 2008). 
These transient techniques are very useful in zebrafish to analyse the effect of 
specific genes during development. But to generate a stable mutant line, TILLING 
(Targetted Induced Local Lesions IN Genome) is the most widely used technique 
(Stemple 2004). 
Zebrafish transgenesis also offers a great tool to study gain of function. 
Transposition is proving a very efficient method for introducing transgenes into the 
germline. Injection of the gene of interest along with the I-SceI meganuclease in 
one cell stage zebrafish egg can produce stable transgenic zebrafish lines (Grabher, 
Joly et al. 2004). 
The ease of manipulation on cellular or molecular levels makes Zebrafish an ideal 
in vivo model in which we can study development, forward and reverse genetics 
and diseases such as cancer (Parng, Seng et al. 2002; Berghmans, Jette et al. 2005). 
 
                                                                                                 Chapter I: Introduction 
 33 
1.3.3 Zebrafish and cancer 
Comparison of the zebrafish genome with the human genome has revealed 
considerable homology in pathways that are often deregulated in carcinogenesis 
such as proliferation, cell movement, differentiation and apoptosis (Amatruda and 
Patton 2008). More specifically, many genes involved in tumourigenesis show 
high conservation with their human orthologues such as cell cycle genes, tumour 
suppressor genes and oncogenes with nearly 100% homology for the functional 
domains (Amatruda, Shepard et al. 2002; Langheinrich 2003; Amatruda JF Apr 
2002). It was shown that zebrafish also develop tumours resembling human cancer 
(Stern and Zon 2003). The similarities of function and regulation of genes 
implicated in human cancer discovered in zebrafish enabled researchers to 
establish this organism as a cancer model. Many cancer models reflecting the 
human disease have been developed in zebrafish. The first created was a model for 
the T-cell acute lymphoblastic leukemia by expressing the c-myc gene in T-cells 
(Langenau, Traver et al. 2003). To date many cancer models are available: APC 
mutated zebrafish developed intestinal, hepatic and pancreatic neoplasia (Haramis, 
Hurlstone et al. 2006), p53 deficiency caused malignant peripheral nerve sheath 
(MPNS) tumours (Berghmans, Murphey et al. 2005). Our laboratory created a 
transgenic line over-expressing human Ras in melanocytes that develop 
spontaneous tumours and can be used to model human melanoma (Michailidou, 
Jones et al. 2009). Xenotransplant models are also available to the zebrafish 
community (Stoletov and Klemke 2008). Various cancer cells were transplanted 
both into young embryos and 30dpf juveniles (Nicoli, Ribatti et al. 2007; Stoletov, 
Montel et al. 2007). 
With its many advantages as a vertebrate model to study development, combined 
with their extended use in large-scale genetic screens (Eisen 1996; Fishman 1999) 
and genetic manipulations (Vascotto, Beckham et al. 1997), zebrafish is potentially 
the most efficient and useful tool that can be used in the search for genes that are 
modifiers of chemotherapy sensitivity and resistance. 
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Figure 1.4: Advantages of modelling cancer in zebrafish. Zebrafish combines 
many attributes of existing model systems: i) Like invertebrate models, zebrafish 
produces a large number of transparent offspring. ii) It has short generation time 
and small size: features that make zebrafish suitable for large-scale genetic and 
chemical screens and facilitate imaging. iii) Like mice, zebrafish has a vertebrate 
anatomy and similar physiological complexity, with genomic conservation with 
human and are susceptible to tumours. These characteristics, combined with the 
practically complete sequenced genome, make zebrafish a great model for cancer 
research (Amatruda, Shepard et al. 2002). 
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1.4 Project aims 
To improve chemotherapy and overcome resistance, it is essential to identify 
factors involved in chemo-resistance or sensitivity. Here, this study proposes to use 
zebrafish in a genetic screen to identify modifiers of chemotherapy. The ability to 
combine genetic screens, carcinogenesis, and chemotherapy in a single organism, 
together with the genetic conservation between zebrafish and human and 
comparable disease aetiology, make zebrafish highly suited for such an 
investigation. 
As discussed above, large-scale genetic screens following exposure of adult 
zebrafish to ENU have revealed that mutations can be induced at a high frequency, 
generating thousands of mutant phenotypes that are carried through in the germ 
line and can be recovered in an F3-generation screen (Figure 1.5)(Driever, Solnica-
Krezel et al. 1996; Haffter, Granato et al. 1996). A wide range of mutants were 
scored during these screens, whereas the project proposed here will answer a 
specific question and should thus be called a focused screen. The main advantage is 
that the mutants recovered will affect specific pathways and mechanisms.  
As described in Figure 1.5, zebrafish adult males will be mutagenised and crossed 
to wild type females to create the F1 generation, which will be heterozygote for the 
mutation (+/-). Heterozygote F1 will then be crossed to wild type animal to create 
the F2 generation. Each crossing will generate a distinct F2 family. Many couples 
will be used from each F2 family to generate an F3 generation. When two 
heterozygote parents will be mated to each other, a quarter of the progeny will be 
homozygote null (-/-) for the mutation. Mutations affecting chemotherapy response 
will be selected by screening the F3 generation with chemotherapeutic agents. 5dpf 
embryos from the F3 will be challenged with Vincristine (Vn) and Camptothecin 
(CT) for 24 hours. An apoptosis assay using acridine orange (AO) was used to 
visualize the effect of the drug treatment on the embryos and score any hypo- or 
hyperresponders. 
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Mutants uncovered in this screen will serve as a platform for future studies. The 
mutations will be mapped and each mutation loci will be assigned to a function 
after characterisation of the mutant. Once characterised, these mutants will provide 
a platform for future research in attempts to improve the success of chemotherapy 
in individual patients. Ultimately, future research will be aimed at developing 
therapeutics that reverse or circumvent chemo-resistance or otherwise sensitise 
tumour cells to chemotherapy. 
 
 
 
Figure 1.5: ENU mediated mutagenesis screen using zebrafish (Haffter, 
Granato et al. 1996). Males were mutagenised with ENU and crossed to wild type 
females generating a heterozygous F1 generation.  F2 generation was created by 
out-crossing F1 to wild type and the F3 generation, resulting from F2 in-cross, was 
screened for mutants.
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Chapter II: Materials and methods 
 
2.1 Reagents 
Procedure Solution Components 
Gel 
electrophoresis 1x TAE 
40 mM Tris Base pH8, 1 mM 
EDTA, 20 mM Glacial Acetic 
Acid 
Embryo 
culture Instant ocean 
40g of sea salt (Tropic marin) in 
1 litre dH2O 
 
Chorion water + 
methylene blue 
0.01 % methylene blue (w/v) 
(Sigma) in instant ocean 
Anesthesia MS222 7.5 mM Tricaine (Sigma) in fish 
water 
Protein 
extraction Lysis buffer 
1 mM HEPES pH 7.4, 1 mM 
EDTA, 15 mM NaCl, 0.5% 
Triton X-100 (v/v) 
DNA 
extraction DNA lysis buffer 
50 mM Tris pH8, 100 mM 
EDTA, 0.5% SDS (v/v), final pH 
7.2 
 
 
Cell culture 
Complete DMEM-
F12 Glutamax 
(GIBCO) 
DMEM-F12 supplemented with 
10% FBS (v/v), 1% Pen/Strep 
(v/v) 
 
Complete L15 
Leibovizt (GIBCO) 
L15 supplemented with 15% FBS 
(v/v), 1% Pen/Strep (v/v) 
 
 
Ponceau staining 
0.02% Ponceau (w/v)(Sigma), 
5% glacial acetic acid (v/v), in 
450 ml dH2O 
Western 
Blot/Histology 1x TBS 
25 mM Tris-Base pH7.5 (Thermo 
Scientific), 136 mM NaCl 
(Thermo Scientific), 2.7 mM  
KCl (Thermo Scientific)  
 TBST 1x TBS, 0.1% Tween-20 (Sigma) 
 
 
 
1x PBS 
137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 2 mM KH2PO4, 
pH7.4 
In situ 
hybridization 20x SSC 
150 mM NaCl, 15 mM 
Na3Citrate,2H2O  
 
PBST PBS with 0.1% Tween-20 (v/v) (Sigma) 
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Table 2.1: General solutions 
2.2 Molecular biology 
2.2.1 Polymerase chain reaction (PCR) 
Gene amplification was achieved in a thermal cycler (PTC-100, MJ Research) 
using the reaction and the program outlined below: 
PCR reaction: Template DNA was added to the following master mix: 
 
 
 
 
 
 
 
 
 
PCR program: 
 
 
 
 
 
 
 
 
Specific changes to cycle number (X) and annealing temperature(x) can be viewed 
in materials and methods section of each result chapter. 
 
 
 
Hot lid 110°C
Denature 94ºC for 5 minutes
Denature 94ºC for 30 seconds
Anneal xºC for 30 seconds                    X cycles
Elongation 72ºC for 1 minute
Elongation 72ºC for 5 minutes
Store at 4°C
10x Buffer (Promega)                     5µl
MgCl2 (25 mM Promega)             2.5µl
dNTPs (10 mM Bioline)               0.5µl
GoTaq Polymerase (Promega)   5unit/µl
Forward primer (15µM)              0.25µl
Reverse primer (15µl)                 0.25µl
dH2O                                              …
DNA <0.5µg/50µl
TOTAL VOLUME                        25µl
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2.2.2 Agarose gel electrophoresis 
Agarose gels were prepared by dissolving agarose (w/v) into 1xTAE buffer (table 
2.1) and heating in the microwave for 5-10 minutes. Ethidium bromide (Fluka) was 
added at 0.5µg/ml once the gel had cooled down to 50°C. Different % of agarose 
gel were used depending on the size of the DNA fragment size. DNA samples were 
then mixed with 5x loading dye (Bioline) and loaded into individual wells along 
with a molecular weight ladder (Hyperladder I or IV, Bioline). Gels were then run 
immersed in 1x TAE in the gel tank (Power pack Consort E132, Gel tank Jencons, 
HU13) and were run until the DNA bands had separated. DNA bands were then 
visualised under UV light using a syngene geneflash UV box and camera. 
2.2.3 DNA extraction and purification from agarose gel 
A GFX purification kit (GE Healthcare) was used to purify DNA from agarose gels 
and solutions. Briefly, gel slices containing the DNA bands of interest were 
dissolved in 300 µl of capture buffer for 10 minutes at 60°C whereas the DNA 
coming from a solution was mixed in 500 µl of capture buffer. This solution was 
loaded onto a GFX column and processed following the manufacturer’s 
instructions. Eluted DNA was stored at -20°C. 
2.2.4 DNA and RNA quantification 
DNA was quantified using a Thermo Scientific Nanodrop™ 1000. This machine 
was blanked using 1µl of dH2O. The DNA sample (1µl) and RNA sample (2 µl) 
absorbance was respectively measured at 260nm and 280nm and yield was given as 
ng/µl. 
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2.2.5 pGEM®-T cloning 
The pGEM®-T easy vector system (Promega)(Appendix, Figure 1) was used to 
clone purified PCR products. The ligation was carried out overnight at 4°C, using 
the following reaction: 
 
 
 
 
 
 
A ratio 1:1 of PCR product and vector was used. According to manufacturer’s 
instructions, the following equation was used to calculate how much PCR product 
should be added to the reaction: 
 
 
 
The multiple cloning site contained the gene coding for the enzyme β-
galactosidase. A successful insertion would inactivate the enzyme and the presence 
of X-Gal pre-added to the LB agar plate allowed a blue/white selection of the 
colonies. 
2.2.6 Transformation 
The ligation mixture was added to pre-thawed chemically competent Escherichia 
coli cells (XL1-Blue supercompetent cells Invitrogen), and incubated on ice for 20 
minutes. These cells were then heat-shocked at 42 °C for 45 seconds and placed 
immediately back on ice for 5 minutes. After 5 minutes at room temperature the 
cells were plated onto a pre-warmed LB agar (Merck) plate (the LB agar contained 
either ampicillin 100µg/ml or chloramphenicol 30µg/ml for colonies-selection). 
The plate was incubated overnight at 37 °C to allow the colonies to grow. 
2x Ligation Buffer              5µl
pGEM®-T vector               …
PCR product                       …
T4 DNA ligase                   1 µl
TOTAL VOLUME           10 µl
× insert:vector molar ratio = ng of insert
ng of vector × kb size of insert
kb size of vector
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2.2.7 Isolation of plasmid DNA: Miniprep 
Single colonies were inoculated into 2 ml of LB-broth containing antibiotics (same 
concentration than for transformation-see above). Cultures were then incubated 
overnight at 37°C, with constant agitation. 1 ml of culture was transferred to a      
1.5 ml eppendorf tube and centrifuged at 13,000g for 1 minute to pellet the 
bacteria. Supernatant was discarded and the remaining bacterial pellet re-suspended 
in 100µl of ice cold Solution I (Table 2.2). The suspended cells were then lysed by 
adding 200µl of Solution II (Table 2.2) and inverting the tube 5-6 times to mix. 180 
µl of neutralising Solution III (Table 2.2) was then added and mixed again by 
inverting 5-6 times. After addition of 200 µl of chloroform and vigorous shaking, 
the mixture was centrifuged for 15 minutes, producing a protein precipitate and an 
upper aqueous layer containing the solubilised plasmid DNA. 450 µl of this top 
layer was transferred to a fresh tube and an equal volume of isopropanol was added 
to precipitate the DNA. The mixture was centrifuged for a further 10 minutes and 
the supernatant removed, leaving a DNA pellet. This pellet was washed with 1 ml 
of 70% ethanol and centrifuged again for 10 minutes. The supernatant was 
discarded and the pellet allowed to air dry. Once dry, the DNA was re-suspended in 
30 µl of dH2O and stored at -20°C. 
 
Solution I Solution II Solution III 
100 mM    Tris pH8 
100 mM    EDTA pH8 
50 µg/ml   RNase A 
0.2 M  Sodium hydroxide 
1%       SDS (v/v) 
3 M potassium acetate 
10%  Glacial Acetic acid(v/v) 
pH 5.5 
 
Table 2.2: Components of each Miniprep solution 
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2.2.8 Digest 
Various restriction enzymes (NEB) were used to confirm successful cloning, to 
linearise vectors and to release insert before ligation. The following reaction was 
incubated at 37 °C for at least 2 hours. 
 
 
 
 
 
 
 
2.2.9 Ligation 
Ligation into an expression vector was carried out using 1 unit of T4 DNA ligase 
enzyme (Roche) and 2 µl 10 x ligase buffer (Roche). Reactions were set up with a 
3:1 ratio of insert to vector (approximately 200ng of vector was used per reaction), 
made up to 20 µl with dH2O and incubated overnight at 15 °C. 
2.2.10 PCR screen 
This method was used to confirm successful cloning into the final vector, which 
generally does not contain a visual method to select positive clones unlike the 
pGEM®-T easy vector system (described in 2.2.5). Single colonies were picked and 
were transferred into a PCR mixture and into LB medium both into a 96-well plate. 
The PCR amplified the insert in colonies containing the insert only. Meanwhile the 
LB-plate was incubated for 4 hours at 37ºC, allowing enough bacteria to grow for a 
Miniprep of the final construct. 
 
 
 
Plasmid DNA          10µg
Enzyme buffer                   1x  
Restriction enzyme            5unit
BSA (if necessary)            0.5 µl
dH2O                                    …
TOTAL VOLUME            20 µl
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2.2.11 Sequencing reaction 
Sequencing was used to check the sequence of final constructs. The following 
reaction and program were performed in a G-Storm PCR machine (GRI Ltd) with 
the ABI BigDye Terminator Cycle Sequencing Ready-reaction Kit (Applied 
Biosystems) using the M13 primers: 
M13 forward: 5’-GTAAAACGACGGCCAG-3’ 
M13 reverse: 5’-CAGTATCGACAAAGGAC-3’ 
Reaction: 
 
 
 
 
 
 
 
Program: 
 
 
 
 
 
The products were precipitated with 1µl of Glycoblue (Ambion) to visualise the 
DNA pellet, 2 µl of 3 M sodium acetate and 50µl of 95% ethanol. After mixing, the 
samples were centrifuged at 13,000g for 20 minutes. The supernatant was 
discarded and the remaining DNA pellet was washed with 100 µl of 70% ethanol. 
This was centrifuged for 15 minutes at 13,000g and the supernatant was discarded. 
The DNA pellets were allowed to dry at RT and were stored at 4ºC. 
Sequencing reactions were processed at The University of Manchester DNA 
Sequencing Facility and the results were analyzed using BioEdit software. 
 
Big Dye Terminator enzyme             2µl
Big Dye Buffer                                  3µl
Primer (3.3µM)                                  1µl
Plamid DNA                                    300ng
H2O                                                     …
TOTAL VOLUME                            20µl
Denature at 96°C for 30 seconds
Denature at 96°C for 10 seconds
Primer annealing at 55°C for 5 seconds          x 30 cycles
Elongation at 60°C for 4 minutes
Store at 4°C
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2.2.12 Isolation of plasmid DNA: Maxiprep 
Large scale plasmid isolation of positive bacterial clones (from the diagnostic 
digest and the PCR screen) was carried out using QIAfilter™ Plasmid Maxi kit 
(Qiagen®) as per manufacturer’s instructions. 
 
2.3 Zebrafish 
2.3.1 Zebrafish husbandry 
Zebrafish were housed at the Biological Services Facility, The University of 
Manchester, under standard conditions described in the zebrafish book (available 
online at http://zfin.org). The fish water was maintained at 28.5 ºC with a 10-14 h 
dark-light cycle. They were fed twice daily with a diet of brine shrimp and flake 
food. Embryos were cultured at 28.5°C in conditioned water called chorion water 
(see Table 2.1) until 6 day post fertilization (dpf) when they were transferred to the 
main aquarium system. 
2.3.2 Breeding and embryo collection 
Adult males and females (2 of each) were placed in crossing tanks (Thoren 
Aquatics, Inc.) and kept separated overnight by a plastic divider. The dividers are 
removed when the lights are turned on in the morning to ensure synchronised 
fertilisation. The box contained a mesh through which the eggs fall through easily 
and were kept safe from the fish until collected. The collection was made 20 
minutes after removing the dividers in order to ensure fertilisation of the produced 
eggs. 
2.3.3 Microinjection of embryos 
Splice morpholinos were injected at 300 µM into the yolk of one to four cell stage 
zebrafish zygotes 
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Messenger RNAs (mRNAs) were injected at 25ng/µl into one-cell stage zygotes. 
These mixtures were supplemented with 0.2% w/v phenol red (Sigma) to facilitate 
visualisation of the volume injected. Micro-injection was achieved using a PLI-90 
Pico-Injector micro-injection station. Subsequently animals were raised under 
standard conditions until analysis at 3dpf. 
2.3.4 Anaesthesia 
Zebrafish embryos and adult animals were anaesthetised with MS222 (see Table 
2.1). Anaesthesia was performed before live imaging of embryos, fixative 
treatment and dissection. 
2.3.5 Acridine orange staining 
Embryos were stained with 3 µg/ml of acridine orange (AO) (Sigma) in fish water 
for 15 minutes then washed three times in fish water. After anaesthesia with 
MS222 (Sigma), AO staining was visualised and imaged using a Zeiss LumarV12 
microscope equipped with an AxioCamera and the AxioVision software. 
2.4 Reverse-transcriptase coupled PCR (RT-PCR) 
2.4.1 RNA extraction from zebrafish tissue and whole embryos 
RNA was extracted from injected embryos and adult skin to provide material for 
cDNA synthesis followed by semiquantitative reverse-transcriptase coupled PCR 
(RT-PCR). 
Total RNA was isolated from a pool of 25 3dpf embryos using RNAeasy Lipid 
Tissue mini kit (Qiagen) as per manufacturer’s instructions. Embryos were 
homogenised in 1 ml of QIAzol (Quiagen) using an electric homogeniser (Ultra-
turrax T8 IKA-WERKE). After 5 minutes at room temperature, chloroform was 
added to the sample which was then centrifuged at 12,000g for 15 minutes at 4ºC to 
be separated into an upper aqueous phase, lower organic phase and a protein 
interface. The RNA upper phase was transferred to a new tube and mixed with 
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equal volume of 70% ethanol. The mixture was then added to the RNeasy spin 
column (Qiagen) and following the manufacturer’s guidelines, RNA was washed 
with a series of provided buffer solutions. Before eluting the RNA in RNase-free 
water (Qiagen), the RNase-Free DNase Set (Qiagen) was used in order to remove 
any remaining DNA in the sample. The DNase digest was performed on the 
column and the DNase was efficiently removed in subsequent washes, leaving pure 
isolated RNA. RNA samples were aliquoted at 1 µg in 10 µl and stored at -80 ºC. 
2.4.2 cDNA synthesis 
Omniscript reverse transcription kit (Qiagen) was used to synthesise cDNA. 
Aliquot of RNA was incubated at 37 ºC for 1 hour in the following reaction: 
 
 
 
 
 
 
 
 
A negative control was produced in parallel of the main reaction without reverse 
transcriptase. 
2.4.3 RT-PCR 
The amplification of gene of interest was made by PCR, using the same reaction 
and program already described in 2.2.1. 1 µl of cDNA was used in the reaction and 
the number of cycles was adapted to each primers used. 
 
 
 
10x RT Buffer                            2µl
dNTPs (5mM)                           2µl
Oligo dT (10µM))                      2µl
RNase inhibitor (1U/µl)             1µl
Reverse transcriptase (4units)    1µl
RNase free H2O                          2µl
RNA (1µg)                               10µl
TOTAL VOLUME                   20µl
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2.5 Histology- paraffin 
2.5.1 Fixation 
Adult fish were first fixed in order to preserve tissue integrity. Animals were first 
sedated in chorion water containing 4% MS222 and cut in two to allow the fixative 
to penetrate the tissue. Following this, samples were transferred into a 4% 
Paraformaldehyde (PFA, MP Biomedicals) in PBS (see Table 2.1) solution and left 
at 4°C for 4 to 5 days. After 3 short PBS washes, samples were transferred into 
0.25M EDTA pH 8 and left at room temperature for 2 days. This treatment de-
calcifies the fish so that bones do not fragment sections and enables smooth, 
efficient sectioning. Following this, samples were immersed in 70% ethanol. At 
this stage samples could be stored at 4°C until required for tissue processing. 
2.5.2 Tissue processing 
In preparation for tissue processing, samples were first placed in embedding 
cassettes, lined with permeable foam to keep them in a fixed position. These 
cassettes were then put through the Tissue Processor (Microm STP 120). The 
program used is outlined in Table 2.3 and lasted 17 hours altogether. Samples were 
dehydrated through a series of ascending concentrations of ethanol (70%-100%), 
followed by three xylene steps to remove alcohol and harden the tissues. In the 
final two steps of the program, samples were immersed in paraffin for a total of 5 
hours to allow complete penetration of the tissue. 
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Step Solution Duration 
1 70% Ethanol 3h30min 
2 70% Ethanol 1h 
3 90% Ethanol 1h 
4 95% Ethanol 1h 
5 100% Ethanol 1h 
6 100% Ethanol 1h 
7 100% Ethanol 1h 
8 Xylene 30min 
9 Xylene 1h 
10 Xylene 1h 
11 Paraffin wax 2h 
12 Paraffin wax 3h 
Total  17h 
Table 2.3: Tissue processor program 
2.5.3 Embedding and sectioning 
Following processing, cassettes were transferred into trays of liquid paraffin wax to 
await embedding. The embedding machine used was a Microm EC 350-1. Larvae 
were placed in a plastic cast containing hot wax and were orientated using fine 
forceps. These paraffin blocks were then left to cool and set on a cold plate 
(Microm EC 350-2) for an hour and then at room temperature overnight. Blocks 
were sectioned using the Microm Cool-Cut HM 355S microtome and stainless steel 
microtome blades (Accu-Edge from Sakura Finetek). Sections were cut at a 
thickness of 5 µm, after which they were picked up with forceps and placed on a 
heated water bath (40°C). Here they could be guided onto labelled pre-treated, 
adhesive glass slides (VWR International Superfrost Plus) using forceps and left to 
dry at 37°C overnight. 
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2.5.4 Immunohistochemical staining 
2.5.4.1 De-paraffinization and rehydration 
Paraffin sections were washed twice in xylene for 8 minutes in order to remove the 
wax. Samples were then rehydrated in descending concentrations of ethanol: 100%, 
90%, 70%, 50%, 30% for 5 minutes each and finally washed in H20. 
2.5.4.2 Antigen retrieval 
To perform antigen retrieval, slides were immersed in boiling 10 mM sodium 
citrate pH 6 for 10 minutes at low power in a microwave. After washes in H20, a 
water-tight border around the samples was drawn to avoid using too much solution 
(ImmEdge, VectorLabs). Sections were next incubated with 3% hydrogen peroxide 
solution (Sigma) for 10 minutes at room temperature in order to quench 
endogenous peroxidase, and washed with H20. 
2.5.4.3 Blocking and primary antibody 
Before blocking, sections were washed in TBST (see Table 2.1) and then blocked 
in 1x Casein (Vector Labs) in TBST for 1 hour at room temperature. The samples 
were then incubated with primary antibody in blocking solution overnight at 4ºC. 
2.5.4.4 Secondary antibody and detection 
After the primary antibody incubation, slides were washed 3 times 5 minutes in 
TBST and then incubated with a secondary pan specific antibody (Vector Labs, 
2.5ml TBS, 75µl normal horse serum, 1 drop of PAN antibody) for 30 minutes at 
room temperature. Meanwhile the ABC (Avidin plus Biotinylated horseradish 
peroxidase Complex, Vector Labs) solution was prepared (2.5ml TBS, 1 drop 
reagent A, 1 drop reagent B) and left to stand for 30 minutes at room temperature. 
Following removal of the PAN antibody, samples were washed 3 times with TBST 
and the ABC reagent was added to the slides and incubated for 30 minutes at room 
temperature. Slides were then washed 3 times with TBST and the DAB peroxidase 
substrate (5ml H2O, 2 drops of buffer stock, 4 drops of DAB, 2 drops H2O2, Vector 
Labs) was added. The DAB brown staining took 3-6 minutes to develop and was 
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monitored under a dissecting microscope. Finally slides were immersed in H2O to 
stop the reaction. 
2.5.4.5 Counterstaining, dehydration and mounting 
The counterstain was performed by immersing the slides in haemotoxylin for 40 
seconds and then put under running tap water for 5 minutes. Tissues were then 
dehydrated in 95% and 100% ethanol for 1 minute each and immersed in xylene 
for a few minutes to remove all traces of ethanol. The sections were then mounted 
with pertex (HistoLab) and a coverslip (VWR), and left to dry for a few hours at 
room temperature ready for imaging. Images were captured using a LeicaDM LB2 
with a Leica camera and a Leica application suite. 
2.6 Cell culture 
2.6.1 HEK 293 cells 
HEK 293 cells were maintained at 37ºC with 5% CO2 in complete DMEM-F12 
Glutamax (GIBCO) medium (see Table 2.1). 
2.6.2 Transfection 
Cells were transfected with FuGENE® HD (Roche) transfection reagent on 50% 
confluent cells as per manufacturer’s instructions. 1 µg of the plasmid of interest 
was used with 4 µl of FuGENE for a total volume of 100 µl in serum-free medium. 
2.7 Immunoblotting 
2.7.1 Protein extraction from human cell line 
Cells were washed twice in PBS and put on ice. 150 µl of lysis buffer (see Table 
2.1), containing protease inhibitors (GE Healthcare) and phosphatase inhibitors 
(Calbiochem), at a concentration of 10 µl/ml, were added to the plate and the cells 
were scraped off with a cell scraper for 30 seconds. Samples were transferred to an 
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eppendorf tube and incubated on ice for 5 minutes. The samples were then 
centrifuged at 13000g for 15 minutes at 4ºC and the supernatant was then placed in 
a new tube and frozen at -80 ºC. 
2.7.2 Protein quantification 
10 µl of protein extract were added to 1 ml of 1x Advanced Protein Assay 
(Cytoskeleton Inc.) in a plastic cuvette (Fisherbrand) and the concentration was 
calculated as per the instructions of the manufacturer. Protein concentration was 
measured at 595nm in a spectrophotometer (Jenway 6305). 20 µg of protein were 
aliquoted in 20 µl of dH2O. 
2.7.3 Western blot 
2.7.3.1 Running 
Samples were defrosted on ice and mixed with 10µl of the NUPAGE LDS buffer 
[400 µl NUPAGE sample buffer (Invitrogen), 200 µl NUPAGE Reducing Agent 
(Invitrogen)] before being boiled at 85oC for 15 minutes. Samples were then 
quickly spun down and loaded on a 4-12% Bis Tris Novex Gel (Invitrogen). 5 µl of 
rainbow protein ladder (GE Healthcare) was loaded as a marker. Samples were run 
in an X- Cell Surelock tank (Invitrogen) filled with 1x NUPAGE MOPS SDS 
Running Buffer (Invitrogen) at 200V for 1 hour. 
2.7.3.2 Transfer 
Immobilon-P membrane (Millipore) was immersed in 100% methanol for 15 
seconds then transferred into transfer buffer (1x Invitrogen Transfer Buffer with 
10% methanol). The gel was removed from the precast casing and placed next to 
the membrane between layers of filter papers and sponge pads presoaked with 
transfer buffer. The protein samples were transferred from the gel to the membrane 
in an X Cell II Blot Module (Invitrogen) filled with transfer buffer for 1 hour and 
15 minutes at 30V. 
                                                                              Chapter II: Materials and Methods 
 52 
2.7.3.3 Membrane blocking, antibody immunoblotting and 
detection 
Efficiency of the transfer was assessed by incubating the membrane in Ponceau 
staining (see Table 2.1) for 1 minute. The stain was rinse off with water before 
blocking the membrane in 5% milk (Marvel) in TBST (Table 2.1) for 1 hour at 
room temperature. 
After blocking, the membrane was incubated with the primary antibody in blocking 
solution overnight at 4ºC. The membrane was then washed 3 times for 10 minutes 
in TBST and incubated with the appropriate horseradish peroxidise (HRP)-
conjugated secondary antibody (GE Healthcare) at 1:5000 in blocking solution for 
1 hour at room temperature. Before ECL (enhanced luminol-based 
chemiluminescent) detection, the membrane was washed in TBST 3 times for 10 
minutes. ECL (Perkin-Elmer) was applied to the membrane as per the 
manufacturer’s instructions and then placed in a dark cassette. The exposure to 
photographic film (Kodak BioMax MR, Sigma) was done inside a dark room and 
the film was developed in a film processor (Optimax, IGP). 
2.7.3.4 Stripping and reprobing 
The membrane was stripped with the stripping buffer [40mM Glycine, 1M NaCl, 
2% NP-40 (v/v)] to remove the first antibody and be able to reprobe with a loading 
control antibody. The membrane was blocked (as described in 2.7.3.3) and 
reprobed with a primary antibody against β-actin raised in mouse (Sigma #A5441) 
together with the HRP-conjugated secondary anti-mouse antibody (GE Healthcare) 
at both 1:10 000 for 30 minutes at room temperature. The membrane was then 
washed and exposed to ECL (see 2.7.3.3). 
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Chapter III: The Screen 
 
3.1 Introduction 
 
Chemotherapy is the mainstay of treatment for metastatic malignancies, and is 
frequently used as adjuvant therapy for the treatment of local cancers. 
Chemotherapy agents are chemically diverse, including both natural products (e.g. 
paclitaxel/Vincristine) and purely synthetic compounds (e.g. cisplatin)(Steel and 
Costanzo 2003). Each drug family has a mode of cytotoxicity and the net effect is  
mainly disruption of DNA transcription, replication and/or segregation resulting in 
cell-cycle arrest and apoptosis (Zhou and Elledge 2000). Ultimately, chemotherapy 
fails the majority of cancer sufferers. Tumour cells re-emerge that are resistant to 
the cytotoxic effects of the drugs and the underlying causes of chemoresistance are 
often multifactorial and frequently obscure (Gottesman 2002). Some resistance 
mechanisms are specific to a single entity but frequently cancer cells acquire 
multidrug resistance, implying that they have undergone alterations in pathways 
common to the metabolism or mode of action of many drugs (see Chapter I). 
Identifying factors that selectively enhance drug uptake or metabolism by cancer 
cells or, alternatively, that protect healthy tissues could minimize non-specific 
cytotoxicity and be important in the clinic. 
Genetic screens present an effective way to assess the relevance of genes in 
response to different drugs. An RNA interference screen across different cancer 
cell lines reported ceramide metabolism as a key regulator in chemosensitivity of 
different drugs such as Paclitaxel, Doxorubicin, 5-FU and Cisplatin (Swanton, 
Marani et al. 2007). Another similar screen isolated 89 genes sensitising lung 
cancer cell lines to Paclitaxel (Whitehurst, Bodemann et al. 2007). The genes 
uncovered from genetic screens can provide platforms for future potential 
therapeutic targets. However, bioavailability and toxicity are the major obstacles in 
drug development. It can often result in the failure of drugs, which look promising 
in vitro, when tested in animals (Bleicher, Bohm et al. 2003). This can be due to 
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modifications and interactions that become apparent in vivo, for example antagonist 
activity, enhancers and suppressors or inactivation during drug metabolism 
(Langheinrich 2003). Unlike screens with cancer cell lines and somatic cell lines, 
where there is the possibility to test hundreds of drugs or genes in a single screen, 
using an in vivo model could probe both host factors (e.g. drug absorption, 
metabolism, tissue–vasculature interactions, and excretion) as well as cell 
autonomous factors (e.g. drug accumulation, DNA-damage repair, apoptosis) 
underlying chemoresistance, and reveal chemosensitising drug targets that are non-
essential to organism survival. 
The purpose of this study is to perform a forward genetic screen in zebrafish 
embryos to identify genes modifying chemotherapy response. Langheinrich et al. 
demonstrated that morpholino-mediated knock-down of p53 in zebrafish embryos 
greatly reduced apoptosis ensuing exposure to camptothecin and other genotoxic 
stresses (Langheinrich 2003). This study demonstrated that reducing the amount of 
a single gene product, whose function in chemoresistance in real human tumours is 
well appreciated, can greatly modify a zebrafish embryo’s response to a clinically 
relevant chemotherapy drug. In summary, the ability to combine genetic screens 
and chemotherapy in a single organism, together with the genetic conservation 
between zebrafish and man and comparable disease aetiology (see Chapter I, 1.3), 
make zebrafish highly suited for such an investigation. 
Previous work from the laboratory (Ahmed, MPhil, 2006) had led to the 
completion of the ENU treatment and the generation of the F1 families, as well as 
the optimisation of screening parameters. The most suitable time point for drug 
treatment was at 5dpf. At this stage, the embryos exhibited the same morphological 
features by overcoming asynchronous development and did not require 
concentration of drugs as high as at 2/3 dpf due to a completely developed 
digestive tract. AO staining was chosen as a quick and easy way to look at 
induction of apoptosis, this dye intercalates into the double stranded DNA and was 
known to be an easy and sensitive assay to visualise apoptosis (Darzynkiewicz, 
Bruno et al. 1992). Vn at 20 µM and CT at 340 nM were chosen due to their 
                                                                                               Chapter III: The screen 
 55 
consistent and efficient induction of apoptosis in zebrafish embryos (Ahmed, 
MPhil, 2006). 
 
3.2 Aim 
The aim of this first chapter was to perform a forward genetic screen using 
zebrafish to identify mutations conferring resistance or sensitivity to chemotherapy 
treatment. 
 
3.3 Materials and methods 
3.3.1 Drug treatment  
In each well of a 6 well plate, 20 embryos at 5dpf were treated for 24 hours using 
Vn at 20 µM and CT at 340 nM. Following the treatment, embryos were stained 
with AO to visualise apoptotic cells (see 2.3.5). 
3.3.2 Storage of zebrafish embryos for genetic mapping 
Zebrafish embryos and adult tail clips were collected into a 1.5 ml eppendorf and 
stored in methanol at -20ºC until DNA extraction. 
3.3.3 DNA extraction from whole embryos 
Embryos were transferred to a PCR plate with one embryo per well, during the 
process the embryos were kept in methanol on ice. Once aliquoted, embryos were 
allowed to stay at room temperature to evaporate the methanol. 60 µl of extraction 
buffer [10 mM Tris pH8, 2mM EDTA, 0.2% Triton X-100, 200 mg/ml Protease K 
(Bioline)] was then added and the plate was incubated at 55ºC overnight. It was 
followed by 10 minutes at 99 ºC to inactivate the protease K and the stock DNA 
was ready to use. 
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3.3.4 DNA extraction from tail clip 
One tail clip was immersed into 400 µl of lysis solution (Gentra Puregene tissue Kit 
Quiagen) with protease K at 20 µg/ml and incubated overnight at 55ºC. Following 
10 minutes at 99ºC to inactivate the protease K, the DNA was frozen overnight or 
longer for storage. Once defrosted, 133 µl of protein precipitation solution (Gentra 
Puregene tissue Kit Quiagen) was added and the mixture was vortexed for 30 
seconds. Samples were then centrifuged for 5 minutes at full speed and the 
supernatant was collected into a new tube and mixed with 400 µl of isopropanol to 
precipitate the DNA. After centrifugation at full speed for 15 minutes, the pellet 
was washed with 70% ethanol and centrifuged again for 10 minutes. The 
supernatant was discarded and the pellet allowed to air dry. Once dried, the DNA 
was resuspended in 250 µl of DNA solution (Gentra Puregene tissue Kit Quiagen) 
and stored at -20ºC. 
3.3.5 Genotyping 
The DNA working concentration for PCR was made by a 1:20 dilution of the stock 
in dH2O. For the rough/low-resolution mapping, pools of sibling and mutant DNA 
were created. Two different pools of 20 embryos for siblings and mutants were 
used by mixing 2 µl of each DNA and made up to 2 ml with dH2O. Simple 
sequence-length polymorphism markers (SSLPs) spaced 20 cM apart across the 
length of the genome (Appendix, Figure 2) were used to identify linkage to a 
specific chromosome (Knapik, Goodman et al. 1998; Shimoda, Knapik et al. 
1999). For the fine/high-resolution mapping, single mutant embryos were 
genotyped. Markers were amplified by the following PCR and ran on Invitrogen E-
gel 4% gels. A guide to positional cloning can be found at http://zon.tchlab.org/. 
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3.3.6 Bioinformatics 
Lasergene was used to create primers, to make alignments, to look at sequencing 
results and to build contigs. NCBI was used to obtain sequences of gene of interest. 
ZFIN (zfin.org) and Ensembl (ensembl.org) were used to locate genes and markers 
in the genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR reaction:
10x buffer (5Prime)                      2µl
dNTPs (10mM Bioline)           3.2 µl
Taq pol (Promega)                   0.5 µl
Forward primer (15 µM)          0.3 µl
Reverse primer (15 µM)           0.3 µl
DNA                                        10 µl
dH2O                                         4µl
TOTAL VOLUME                    20 µl
Hot lid 110°C
Denature 95ºC for 1 minute
Denature 95ºC for 25 seconds
Anneal 60ºC for 25 seconds                    35 cycles
Elongation 72ºC for 35 seconds
Elongation 72ºC for 5 minutes
Store at 4°C
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3.4 Results 
3.4.1 The screen 
3.4.1.1 Validation of the screen 
The ultimate goal of this screen was to identify new genes influencing 
chemotherapy by analysing the effect of CT and Vn on zebrafish embryos. Mutant 
families of interest should display either a sensitive or a resistant phenotype to the 
drug treatment.  Preliminary experiments were essential in order to be familiar with 
these phenotypes and to recognise potential mutant families. 
3.4.1.1.1 Validation of the sensitive phenotype with verapamyl 
A sensitive phenotype was assessed by using the drug verapamyl, an inhibitor of 
MDR1 protein (Sauna, Smith et al. 2001). Preliminary studies on zebrafish showed 
that high concentration of verapamyl combined with Vn was toxic to zebrafish 
embryos (Ahmed MPhil, 2006). By inhibiting the trans-membrane MDR1 protein, 
which is part of the ABC transporter family, drug efflux should be repressed and 
will sensitise the embryos to the effect of Vn. 
Verapamyl was used alone or in combination with Vn to compare the phenotype of 
embryos treated with Vn only. The optimal dose of verapamyl showed no toxicity 
and the embryos treated with verapamyl were sensitised to Vn (Figure 3.1). 
Verapamyl conferred sensitivity to the drug treatment and gave a reliable model to 
identify potential sensitive mutants during the screen. 
3.4.1.1.2 Validation of the resistant phenotype with in crossed +/-p53 fish. 
To produce a resistant phenotype, an in-cross of p53-/+ animals was used to 
produce a quarter of embryos lacking p53. p53 activates apoptosis and its depletion 
should therefore down regulate the pathway and lead to a resistant phenotype 
(Langheinrich 2003). Progeny from the in-cross were treated with Vincristine and 
Camptothecin, or DMSO as a control. DMSO treated embryos showed no sign of 
apoptotic cells after AO staining (Figure 3.2 A). Most of the embryos showed a 
normal response to the drug treatment, with apoptotic cells in the gut, gills, fins, 
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and skin (Figure 3.2 B) whereas approximately one quarter of the progeny, as 
anticipated, showed a similar response to control embryos (Figure 3.2 C). Thus, the 
loss of p53 conferred resistance to the drug treatment and therefore provided a 
good model to detect resistant phenotype during the screen. 
 
3.4.1.2 Mating strategy 
Males from both AB and TL background were ENU mutagenised and mated to AB 
and TL females respectively, generating pure AB and TL heterozygous F1 families. 
The F1 (3-6 month old) were then inter-crossed and created a hybrid F2 generation 
(40-60 individuals per family) with a mixed genetic background sharing features 
from both AB and TL (Figure 3.3). This inter-cross plays an essential role later on 
in the genetic mapping process (see 3.4.2). In all, 200 different hybrid F2 families 
were created. Each family was in-crossed and the F3 generation was grown to 5dpf 
and screened with two chemotherapeutic drugs Vincristine and Camptothecin to 
identify resistant or sensitive mutants. 
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Figure 3.1: Verapamyl sensitisation. (A) Image of whole 5dpf zebrafish embryos 
stained with AO and imaged by fluorescence microscopy (GFP). Scale bar= 
200µm. (B) Grayscale images were used to enhance the fluorescence. Zoom on the 
trunk and gut of 5dpf embryo treated for 24 hours with (i) DMSO control, (ii) 
verapamyl at 15µM, (iii) 20µM Vn and (iv) 20µM Vn and 15µM verapamyl and 
stained with AO. Although DMSO and Verapamyl treatment alone did not show 
any sign of toxicity, embryos treated with the combination of verapamyl and Vn 
displayed more apoptotic cells (white arrows) in the gut and throughout the skin 
than the embryos treated with Vn only. Scale bars= 50µm 
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Figure 3.2: Resistant phenotype. 5dpf embryos incubated with (A) control 
DMSO showed no sign of apoptosis. The majority of embryos treated with Vn and 
CT showed apoptotic cells throughout the body (B) whereas a quarter of the 
embryos being p53-/- (C) display a resistant phenotype. Scale bars= 200µm 
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Figure 3.3: Mating strategy. AB and TL males were mutagenenised and crossed 
to AB (striped fish) and TL females (dotted fish) respectively to generate the F1. 
The F1 was crossed to create 200 hybrid F2 families. Each family generated the F3 
generation that was challenged with chemotherapeutic drugs.  
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3.4.1.3 Mutant identification 
The F3 embryos were treated at 5dpf with Vincristine 20µM and Camptothecin 
340nM, and then stained with acridine orange to visualise apoptotic cells. 
Whenever it was possible, up to 10 F2 couples were bred and the entire progeny 
was drugged, stained with AO and screened for mutants. Many mutant families 
were identified but the analysis was not further pursued for most of them (Table 
3.1). Some mutants presented morphological defects, such as incomplete 
development of the gut, craniofacial, or heart defects. These mutants were 
discarded to avoid any false results due to incomplete digestive track or physical 
impairment that might interfere with the drug metabolism. A few families 
presented pigment deficiency and were easy to detect but as they did not respond 
differently to the drug treatment, they were also discarded. Many families 
presented resistance or sensitisation to the treatment but the phenotype appeared to 
be inconsistent after repetition and these families were also discarded. Only 
families 127, 128 and 247 were kept for further analysis due to an obvious and 
consistent sensitive phenotype. Mutants respectively called AO127, AO128 and 
AO247 were further described and analysed. 
3.4.1.3.1 Family 127- Mutant AO127 
Mutant AO127 was the easiest to detect due to its very bright phenotype; the 
uptake of AO was observed throughout the whole body (Figure 3.4 B) and every 
cell seemed much brighter compared to WT embryos (Figure 3.4 A). However, the 
mutant embryos in control DMSO also displayed an increase in AO uptake (Figure 
3.4 C-D) suggesting that AO127 phenotype is independent of drug treatment. 
After verification of the consistency of the phenotype, mutants and wild type 
embryos were identified and collected in large quantity for genetic mapping. Some 
spare embryos were added to the nursery to be grown to the adult stage to assess 
their viability. In-crossing adult F3 animals generated more mutants creating a 
homozygous line and therefore demonstrating that AO127 mutants could reach the 
adult stage and breed normally. 
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3.4.1.3.2 Family 128- Mutant AO128 
After drug treatment and AO staining on the family 128, a quarter of the F3 
embryos were identified with a curved body and presented a bigger uptake of AO 
as shown in the figure 3.5. Fluorescent spots were clearly visible on the fins and 
throughout the skin in the mutant compared to the WT. Mutants and wild type 
embryos were collected for genetic mapping. 
3.4.1.3.3 Family 247- Mutant AO247 
The mutant AO247 appeared to be quite different from the first two mutants 
identified. The main difference resided in the location of the increased uptake of 
AO. Indeed AO was more absorbed at the end of the colon (Fig 3.6 D), forming a 
ring of bright cells. As shown in the figure 3.6 C and D, it was quite difficult to 
classify this mutant as sensitive or resistant, the ring of cells at the end of the colon 
appeared more sensitive to the treatment, however the rest of the gut, or even the 
skin seemed to retain less AO and might be therefore resistant to the drugs. AO247 
mutants were collected for genetic mapping. 
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F3 
family Brief description 
#1 morphological mutant: incomplete gut 
#3 inconsistent sensitization 
#53 inconsistent sensitization 
#58 inconsistent sensitization 
#117 morphological mutant: small eyes and incomplete gut 
#126 inconsistent resistance 
#127 sensitive 
#128 sensitive 
#130 morphological mutant: cranio-facial defect, little eyes, flat head 
#135 morphological mutant: incomplete gut 
#142 morphological mutant: little eyes, no liver, strange muscle shape, big yolk 
#144 morphological mutant: cranio-facial 
#145 morphological mutant: cranio-facial 
#158 inconsistent sensitization 
#165 morphological mutant: heart defects 
#166 morphological mutant: big yolk, heart oedema 
#170 Inconsistent resistance 
#172 morphological mutant: heart defect 
#174 morphological mutant: cranio-facial defect, little eyes, flat head 
#185 morphological mutant: strange body shape 
#200 inconsistent sensitization 
#202 inconsistent sensitization 
#247 ring of apoptotic cells at the end of the colon 
#253 inconsistent sensitization 
#290 pigment deficient mutant 
#292 pigment deficient mutant 
#293 pigment deficient mutant 
#294 pigment deficient mutant 
#295 pigment deficient mutant 
#302 pigment deficient mutant 
 
Table 3.1: List of identified mutants. Brief phenotypic description of identified 
mutants. Bold font only for the mutants that were kept and further analysed. 
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Figure 3.4: Phenotype of mutant AO127. 5dpf AO127 and wild type embryos 
were drug treated with Vn 20µM + CT 340nM (A-B, scale bars= 200µm) or 
DMSO (C-D, scale bars= 50µm) for 24h and stained with AO. AO127 mutants (B) 
showed a higher uptake of the dye in most of the cells throughout the entire body 
compared to WT (A). Mutants stained with AO after DMSO treatment (D) 
displayed a similar phenotype compared to mutants treated with drugs (B). Mutant 
AO127 showed an uptake of AO independently of drug treatment. 
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Figure 3.5: Phenotype of mutant AO128. 5dpf embryos from the 128 family were 
treated for 24h with Vn 20µM + CT 340nM and stained with AO. A quarter of the 
progeny (A) was more sensitive to the drugs compared to the wild type embryos 
(B). Scale bars= 200µm 
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Figure 3.6: Phenotype of mutant AO247. 5dpf embryos from the 247 family were 
treated for 24h with Vn 20µM + CT 340nM and stained with AO. Compared to the 
wild type (A), the mutant displayed a growth of skin at the end of the colon region 
when observed with brightfield light (B). Under fluorescence the mutant showed a 
ring of cells positive for acridine orange (D) whereas the wild type presented a 
normal uptake of the dye (C). 
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Once a mutant was found, the heterozygous parents were isolated and kept 
separated from the other fish. The carrier parents were conserved for future 
breeding and crossed in order to provide mutant embryos with a traceable genetic 
background. The fine mapping step can need between 700 to 1000 embryos 
therefore new carrier couples needed to be created and identified to provide a 
constant production of mutants. Each parent was out-crossed to wild type fish and 
their progeny were screened for carriers and new heterozygous couples were 
created for the production of mutant embryos. 
 
3.4.2 Genetic mapping 
Genetic mapping was used to map the location of the mutation as a first step 
toward identifying the mutated gene. The first step of the mapping is called bulked 
analysis and consists in scanning the genome with genetic markers. Genetic 
markers are variations in the genome that can be used to identify individuals or 
species. They are small DNA sequences like SNPs (single nucleotides 
polymorphisms) or SSLPs. Zebrafish SSLPs, called Z-markers, spaced every 
20/40cM on the 25 zebrafish chromosomes were used for the mapping presented in 
this chapter (Appendix, Figure 2). In contrast to previous screens, as described in 
Figure 1.5, the focused screen presented here used two different strains of 
zebrafish. Indeed ABs and TLs fish inter crossings were used to generate the F3 
generation (Figure 3.3). AB and TL are two different strains with different 
polymorphisms, the hybrids of the F2 generation will then receive a chromosome 
from each F1 parents, one from AB and one from TL. With crossing overs 
happening during meiosis, this F2 generation will generate gametes with mixed 
genetic background containing alleles coming from both strains (Appendix, Figure 
3). The closer 2 genetic markers are to each other, the higher the chance they will 
be inherited together. The mutation will thus always carry the same genetic 
background in which it was first created and will be linked to the genetic marker 
nearby (Appendix, Figure 3). Linkage will be then visualize by PCR gel analysis in 
which each genetic marker will be amplified by flanking primers. The presence of 
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linkage will be signalled when mutant samples have one amplified band and wild 
type samples will show a different profile (2 bands). The difference in the number 
of bands is related to the marker defining the strain in which the mutation was 
originally created.  
By using pools of mutant and wild type DNA, the low resolution mapping can 
identify the chromosome containing the mutated gene by genetic linkage and 
narrow the region to a critical interval by looking at the number of recombinants. 
When an interval is properly defined between two markers, the fine resolution 
mapping takes over. Many more embryos are needed in order to narrow the region 
to a decent length by running new markers on individual embryos and decreasing 
the number of recombinants along the way to the mutation. A candidate gene 
approach was used only when the interval was small enough to present a couple of 
genes. 
All mutants found from the screen were collected in sufficient number to start the 
low resolution mapping. Mutants AO128 and AO247 encountered difficulties 
during the mapping process and the mapping of AO127 was successful. All 
mapping results are described below. 
3.4.2.1 Mapping of mutant AO127 
Mutants and wild type pools of DNA were scanned using the panel of Z-markers 
selected for the low resolution mapping (Appendix, Figure 2). Linkage to 
chromosome 13 was established with the marker Z9564 (Figure 3.7 A) and 
individual DNA from 50 mutant embryos was scored for recombinants using the 
critical markers to confirm linkage. A recombinant in this context is a mutant in 
which recombination events have moved apart the mutation from the marker which 
therefore does not appear linked. Markers which are far from the mutation should 
yield more recombinants than markers which are close to the mutation.  Markers 
that are on opposite sides of the mutation should give different sets of 
recombinants, and markers that are on the same side of the mutation should share 
recombinants.  
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New Z-markers positioned around Z9564 were used to genotype 119 embryos and 
by counting the number of recombinants, a genetic map was built up and a critical 
region was narrowed down to 6cM between the marker Z26183 (28.8 cM) and 
Z46765 (38.4 cM) (Figure 3.7 B). 
200 genes were located on this interval; this high number of candidates rendered 
the fine mapping necessary in order to reduce the interval. 
Increased rates of recombination are more advantageous for high-resolution 
mapping due to the proximity of the markers used; new mapping couples were 
therefore created by growing the F3 generation to generate F4 embryos with a 
higher recombination rate. Parents were genotyped for a few chosen markers of the 
interval and the more informative females and males were selected to form couples 
and generated embryos for fine mapping. 
Z43620 and Z61058 gave respectively 4 and 1 recombinants out of 88 embryos 
(Figure 3.8) and this region was then closely investigated. Some markers seemed to 
yield wrong number of recombinants. Indeed the number of recombinants must 
decrease from both extremities of the map to a low number of recombination at the 
position of the mutation.  With a closer look at the map generated, some markers 
such as Z54895 and Z43620 gave incoherent results due to their position on the 
map (Figure 3.8). With the given results, Z54895 and Z43620 should logically 
precede the marker Z46055 so the number of recombinant would decrease. This 
suggested the presence of re-arrangement in the region or a wrong annotation of the 
genome on Ensembl. Due to the presence of scaffolding regions on both sides of 
Z54895 and Z61058, mistakes in the building of this region which would lead to 
wrong annotations can be suspected (Figure 3.8). 
A search for synteny around this region was undertaken to build the interval of the 
mutation properly. The peptide sequence for the gene CST7 in zebrafish was used 
to find orthologues in human and mouse using BLAST (Ensembl). Then genes 
sharing synteny in both human and mouse near CST7 were used to find 
orthologues back in zebrafish. Attempts on many genes failed, but by using the 
mouse and human gene GINS1, a region containing the same gene and located 
50Mb away on the zebrafish chromosome 13 showed linkage (Figure 3.9). New 
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markers (zC270C19-SSR2, SSR5) were designed to genotype this new region and 
both scored 1 recombinant out of 148 embryos narrowing the interval down to 
140,850bp within the contig BX.225965.13 revealing the presence of two genes 
only: zgc:113369 and LOC: 571285 (Figure 3.9). 
 
Zgc:113369, coding for the zebrafish protein ribonuclease T2 (rnaset2), was the 
first gene to be sequenced. A transversion TA was found in the mutant cDNA 
inserting a stop codon (Figure 3.10). The mutation was then confirmed in genomic 
DNA, all parental samples being heterozygous, wild type siblings being 
heterozygous or homozygous without mutation, and the mutants being 
homozygous for the mutation (data not shown). 
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Figure 3.7: Low resolution mapping of AO127. A: Gel picture of the PCR 
showing linkage to the marker Z9564 in the mutant pools. B: The first genetic map 
generated using the number of recombinants from each marker to locate the 6cM 
interval of interest between Z26183 and Z46765. 
 
 
 
 
 
m
al
e
fe
m
ale
Mu
ta
nt
 
po
ol
 
 
 
 
 
 
 
1-
20
M
ut
an
t p
oo
l 
21
-
40
W
T 
po
o
l 
1-
20
W
T 
po
o
l 
21
-
40
A
B
                                                                                               Chapter III: The screen 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Fine mapping of mutant AO127. The incoherent number of 
recombinants yielded by Z54895 and Z61058 showed presence of rearrangement. 
The presence of scaffolding regions (red squares at 5.20Mb and 5.70Mb) might 
have been at the origin of a wrong build of the genome on Ensemble between these 
two markers. 
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Figure 3.9: Search for synteny: A search for synteny was undertaken in order to 
rebuild the region of interest. The peptide sequence for the zebrafish gene CST7 
localised in the misplaced region was used to find orthologues in human and mouse 
(top panel). Genes sharing synteny in both human and mouse near CST7 (green 
star) were used to find orthologues back in zebrafish. The gene GINS1 (green box) 
was found to be co-localized with the gene CST7 in both mouse and human and 
appeared to be also in zebrafish on the chromosome 13 but 50Mb away. The 
genotyping using new markers (zC270C19-SSR2, SSR5) resulted in 1 recombinant 
on both side of the contig BX.225965.13 and narrowing the interval of the mutation 
down to 140,850bp. 
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Figure 3.10: Sequencing of the gene zgc:113369. A premature stop codon was 
found in the gene coding for rnaset2 in the mutant cDNA. 
 
 
 
3.4.2.2 Mapping of mutant AO128 
The same set of Z-markers (Appendix, Figure 2) as used for AO127 was used for 
the low resolution mapping. Linkage to the chromosome 1 was established with the 
marker Z6802 and 96 individual mutants were genotyped using this marker to 
confirm linkage showing 17 recombinants at this location (Figure 3.11). More 
markers from the same region were used but gave very little information as most of 
them were non-informative (Figure 3.11). New markers were used and the interval 
of interest was narrowed to a region less than 10cM between the marker Z53038 
and K121K17-SSR1. The genotype of 96 embryos yielded zero recombinant at the 
marker Z6283 and the region was therefore inspected more closely. A few genes 
only were located around this marker and a candidate approach was therefore 
adopted. The 5 genes underlined in green in figure 3.12 were sequenced but no 
mutation was found which led to the conclusion of another case of missing 
sequence or mis-assembling of the region. Search for synteny was undertaken but 
no gene close to Z6283 made a succesful pair in the human or mouse genome. 
Wild type rnaset2
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The next step was to BLAST some of the genomic scaffolds near Z6283 to rebuild 
the region. 4 BAC clones were identified and successfully assembled together and 
seemed to be located 1Mb away from Z6283 (Figure 3.12 and figure 3.13). New 
markers were designed (SSR2 and SSR4) for these BACs and the genotyping 
yielded zero recombinant (Figure 3.13). All genes between these SSR markers 
were sequenced (underlined in green) but no mutation was found. At this stage, the 
mapping of AO128 was abandoned. 
 
3.4.2.3 Mapping of mutant AO247  
The mapping of AO247 was processed the same way but difficulties during the low 
resolution mapping made the discovery of the mutation impossible. The set of Z 
markers used for this step was run and did not yield any linkage. New markers 
were designed to replace some of which were not informative in order not to miss 
any region of chromosomes. All chromosomes were screened with informative 
markers spaced apart from 20cM. When still no linkage was found, the mapping of 
AO247 mutant was abandoned. 
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Figure 3.11: Low resolution mapping of AO128.  The genetic map generated 
from the bulked analysis located the position of the mutation in a 6cM interval of 
interest between Z53038 and Z55633. 
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Figure 3.12: Fine mapping of AO128. Candidate gene approach failed as all 
genes (underlined in green) located closed to Z6283 did not yield any mutation 
after sequencing. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: BLAST search identified missing BAC clones belonging to the 
interval. 4 BAC clones were identified and assembled together in order to rebuild 
the region. New markers SSR2 and SSR4 yielded zero recombinant and the genes 
in this interval were sequenced (underlined in green). 
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3.5 Discussion 
3.5.1 Has the screen worked? 
The present screen has identified only 3 mutants, only one of them went through 
the mapping process completely and the other two mutations remain unknown. 
Moreover, AO127 mutant showed a phenotype which was due the AO staining and 
not to the drug treatment. These two points might bring up the obvious question: 
Has this screen supposed to identify modifiers of chemotherapy worked? 
The number of morphological and pigment mutants described in table 3.1 indicated 
that the mutagenesis has worked and has indeed generated mutants. But the exact 
efficiency remained unknown. The crossing between the AB and the TL strain was 
performed to visualise the mutagenesis rate. It was calculated by counting the F2 
families exhibiting a TL phenotype, TL containing the recessive leotl mutation and 
exhibiting dots instead of stripes. The mutation rate was set to a 1:500, meaning 
that 20% of the genome was screened in 100 families (Asif Ahmad MPhil). In this 
case then, about 40% of the genome has been screened in the 200 F2 families. This 
approximated rate can be accurate in large scale screen as they usually look at 
different pigmentation mutations to rate the efficacy of the mutagenesis (golden, 
sparse), but even then the initial rate is expected to be an overestimation (Haffter, 
Granato et al. 1996). In the latest large scale developmental screen described, the 
pigmentation mutation frequency suggested 90% saturation, but the overall 
frequency of alleles suggested only 50%. If the initial prognostic on the mutational 
rate was 40% in the presented screen for modulators of chemotherapy, the actual 
rate might mean that less than 20% of the genome was screened. This indeed 
represents a small number of genes covered by this screen and a major limiting 
factor to identify genes of interest. 
Additionally, the main limitation of doing a genetic screen in zebrafish is 
redundancy (Haffter, Granato et al. 1996). Some of the mutations could have 
affected a gene with a complete or partial functional homologue somewhere else in 
the genome and therefore generated only a weak or no phenotype. 
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Using a combination of drugs for the treatment instead of a single agent might have 
caused problems too. CT and Vn were originally chosen because they are causing 
cell death by two different mechanisms. Their targets, Topo I and tubulin 
respectively, have a highly conserved sequence between man and zebrafish (Asif 
Ahmed MPhil). One mutation affecting one drug only could have been masqued by 
the combination. 
3.5.2 Mapping troubleshooting 
The genetic mapping of AO127 and AO128 was problematic due to the zebrafish 
genome assembly, slowing down the fine mapping process or preventing the 
discovery of the affected gene respectively. 
The duplication of the zebrafish genome (Amores, Force et al. 1998; Meyer and 
Schartl 1999) made it difficult to generate a reliable annotated genome and the 
Ensembl Zebrafish Genome is still preliminary and many misjoints and mis-
assemblies are still present. The fine mapping of mutants AO127 and AO128 
exposed the difficulty to map a mutation in a faultily built region of a chromosome 
and showed how a search of synteny can overcome the dilemma. Further mapping 
work could be done on AO128 to find the missing sequence, but it would have to 
wait until the release of Zv9, the new zebrafish integrated whole genome assembly 
from Ensembl (www.ensembl.org/). 
 
The analysis of mutant AO247 was abandoned because of the impossibility to find 
linkage during the rough mapping. The original set of markers was run without 
success, suggesting a fundamental problem in the mating process. 
In zebrafish, the recombination rate was shown to be sex-specific with a higher 
recombination rate in females than in males (Singer, Perlman et al. 2002). An 
extensive use of female carriers will therefore increase the rate of recombination 
which can badly interfere with the low resolution mapping where low rates of 
recombination are essential for the markers to detect linkage. The problem of 
finding a linkage in these mutants might come from the use of female carrier in the 
F2 to produce the F3 generation. The average distance covered by a Z-marker in a 
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male map is 19cM, and the female-to-male ratio in zebrafish is 2.74:1, which 
means that using F2 females to generate the F3 generation would reduce the 
detection interval to 7cM. The markers used for the rough mapping are 20cM 
spaced apart, which makes them too distant from one another to detect linkage 
effectively. 
The F2 males have crossovers between their AB/TL hybrid gametes with a low rate 
of recombination allowing a marker to detect the mutation from a great distance. 
Once this F2 male is crossed to an F2 female, the level of recombination will 
increase by 2.74 in the progeny and drown the mutation in a complex genetic 
background making it impossible for the marker to detect it. 
Instead, crossing F2 males to F1 heterozygous females will give to the progeny 
more chance to have a less mosaic background (Figure 3.14) (Willer, Lee et al. 
2005). 
 
Another solution for the mapping of AO247 would be the use of single nucleotide 
polymorphism (SNP) instead of SSLP as genetic markers. SNPs are single base 
pair variation of the genome of normal individual, they occur more often than 
SSLPs and offer great advantages for genetic mapping such as using high 
throughput genotyping assays (Brookes 1999). The extensive sequencing of the 
zebrafish genome discovered 52000 SNPs which are available on the CASCAD 
pipeline (Guryev, Berezikov et al. 2005; Ekker 2008). The Sanger institute in 
partnership with Affimetrix are developing a SNP Chip assay that will be available 
for zebrafish (Ekker 2008). This SNP Chip technology will allow the use of many 
more markers than the traditional use of SSLPs, with quicker results and could be 
of use in the case of AO247. 
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Figure 3.14: New mating strategy. Schematic of a better mating strategy allowing 
Z-markers to cover greater distances during the low resolution mapping. 
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3.5.3 Zebrafish deficient for rnaset2 uptake more AO 
Acridine orange was used as a quick assay to detect apoptosis in live embryos. It 
has been shown to bind to fragmented pieces of DNA and was therefore reported as 
an apoptosis marker (Abrams, White et al. 1993). However, the uptake of AO in 
rnaset2 deficient embryos happened independently from apoptosis induction, 
suggesting that the increased fluorescence observed might be due to another 
property of AO. Indeed, AO is a basic dye that also accumulates in acidic 
compartments such as lysosomes in vivo (de Duve, de Barsy et al. 1974). 
There are three classes of ribonucleases, RNase A, RNase T1 and RNase 
T2, the latest standing out by its specific activity at acidic pH only (McClure, 
Haring et al. 1989). Human RNASET2 has been described as a putative lysosomal 
hydrolase and therefore a mutated form of this ribonuclease could be at the origin 
of an increase in number or size of lysosomes resulting in an uptake of AO 
(Campomenosi, Salis et al. 2006; Lubke, Lobel et al. 2009). 
RNASET2 has been studied by a few groups for the past 8 years, but its 
physiological role is still unclear. Recently, RNASET2 deficiency in human was 
shown to result in a leukoencephalopathy that arises in infancy characterised by 
multifocal bilateral white matter lesions (Henneke, Diekmann et al. 2009). 
Human RNASET2 and ACTIBIND, a fungus RNaseT2, have also been identified 
as a tumour suppressor gene in various cell lines, as well as a metastasis and 
angiogenesis inhibitor (Acquati, Possati et al. 2005; Smirnoff, Roiz et al. 2006; 
Schwartz, Shoseyov et al. 2007). 
The physiological role of rnaset2, along with its implication in cancer, using the 
rnaset2 deficient zebrafish previously described, were investigated and are 
discussed in the next 2 chapters. 
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Chapter IV: Characterisation of rnaset2 
deficient zebrafish 
 
4.1. Introduction 
Lysosomes are membrane bound organelles, they are the main compartment for 
intracellular degradation and recycling of cellular components. Lysosomal 
hydrolases are responsible for the degradation upon fusion of lysosomes with 
phagosomes and endosomes. Lysosomes contain over 60 or more hydrolytic 
enzymes active at the acidic pH such as phospohatases, nucleases, proteases, lipase 
etc...(Bainton 1981). Lysosomes play an essential role in autophagy, responsible 
for the defense against microorganisms, the degradation of molecules, whole 
organelles and subsequent salvaging of metabolites, and autolytic programmed cell 
death (Lubke et al. 2009)(see Chapter I, 1.1.2.3). Lysosomes have also been 
involved in apoptosis through leaking of their protease cathepsins and activation of 
the intrinsic apoptosis pathway (Leist and Jaattela 2001). Lysosomes seem to play 
an essential role in cell death and autophagy and any deregulations in these 
processes have grave consequences. Some 50 genetic lysosomal diseases, 
collectively termed lysosomal storage disorders (LSDs), have now been recognized 
which affect 1 in every 5,000 to 7,000 live births in the USA (Futerman and van 
Meer 2004; Ballabio and Gieselmann 2009). Inborn lysosomal defects result in 
disease through the accumulation of non-degraded macromolecules. Typically this 
is due to a deficiency in any one of the lysosomal hydrolases, such as  β-
glucosidase in the Gaucher disease (Brady 1997), but can also be due to defective 
lysosomal membrane proteins for example the cholesterol transporter NPC2 
(Nieman-Pick type C) as the origin of the NPC disease (Carstea, Morris et al. 1997; 
Loftus, Morris et al. 1997). The NPC1 trasporter function remained enigmatic but 
some recent work suggested that it might affect the intracellular calcium 
concentration (Hayashi-Nishino, Fujita et al. 2009). 
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The disease symptoms depend generally on the nature of the accumulated 
substrate, giving a unique clinical and pathological diagnostic for each LSD. The 
Pompe disease, for example, is characterised by an accumulation of glycogen, 
resulting in expected muscle pathology due to the prominent role of glycogen in 
muscles (Hirschhorn and Reuser 2001). Generally multiple organs are affected 
leading to severe symptoms and premature death. Central nervous system (CNS) 
involvement is very common with neuronal degeneration being apparent (Walkley 
2009). While the deficient gene and the nature of the accumulating product are 
known in the majority of LSDs, the events that lead from macromolecule 
accumulation to disease are still mysterious. 
Ribonucleases are proteins that catalyse the degradation of RNA and three 
ribonuclease families have been described (Irie 1999). RNase A family is cytosolic 
and has vertebrate origins with a selective activity for pyrimidine at the optimum 
pH of 7/8. RNase T1 family was described as a bacterial ribonuclease, with an 
activity at similar pH than RNase A and with guanylic acid specificity. Of all the 
ribonuclease families, the RNaseT2 family is the only one active at acidic pH 
(McClure, Haring et al. 1989) and consequently, the human RNASET2 was 
suggested to be a putative lysosomal hydrolase (Campomenosi, Salis et al. 2006; 
Lubke, Lobel et al. 2009). Subcellular fractionation of human RNASET2 showed 
presence of the protein in the secretory pathway (Campomenosi, Salis et al. 2006) 
and immunofluorescence microscopy confirmed these last results (unpublished 
data) suggesting strongly that RNASET2 is a lysosomal protein. In zebrafish, two 
proteins were identified with homology to the human RNASET2, Dre1 on 
chromosome 15 with 26% and Dre2 on chromosome 13 with 45% homology 
(Hillwig et al. 2009). The rnaset2 deficient mutant described in this study has a 
mutation in the Dre2 gene, the most conserved sequence in human showing a very 
stong homology in catalytic domain among other species (Figure 4.1). 
Deficiency in RNASET2 in infants resulted in a leukoencephalopathy with 
psychomotor impairment, micro- or normocephaly, spasticity and epilepsy. The 
brain abnormalities included multifocal white matter lesions, bilateral cysts in the 
anterior temporal lobe, enlarged inferior horns and calcifications (Henneke et al. 
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2009). Magnetic resonance imaging (MRI) was used to detect the lesions in human 
patients, and the same technique was developed to analyse the brain of adult 
zebrafish (Kabli, Alia et al. 2006). Up to now, no animal model has been generated 
to study this disease. 
 
4.2 Aim 
The aims of this chapter are to characterise rnaset2 deficiency in zebrafish and test 
whether this mutant can be used as a model to study leukoencephalopathy in 
RNASET2 deficient children. 
 
4.3 Materials and methods 
4.3.1 Site directed mutagenesis 
Full length zebrafish rnaset2 cDNA was purchased from Open Biosystem 
(http://www.openbiosystems.com). The wild type cDNA was mutated using 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) by following the 
manufacturer instructions. 
∆RNaseT2T304A was created with the following primers: 
CCCAAAATTTTGGAATTATGAATGGACGAAACATGGGACC, forward 
GGTCCCATGTTTCGTCCATTCATAATTCCAAAATTTTGGGG, reverse 
This mutated version of rnaset2 reproduced the exact same mutation found in 
AO127 and was used as a control in the rescue experiment. 
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4.3.2 Synthesis of mRNA from cDNA template 
The plasmid containing full length cDNA was digested to be linearised on the 3’ 
end (see 2.2.8). Following the instructions from the mMessage mMachine T7 kit 
(Ambion), the reaction below was incubated for 2 hours at 37 ºC: 
 
 
 
 
 
 
Following the incubation, 1 µl of Turbo DNase provided in the kit was added to the 
reaction for 15 minutes at 37 ºC in order to degrade the template DNA. 
To purify the RNA, nuclease-free water was added to the sample to create a final 
volume of 100 µl. Following the instructions from the RNeasy Mini Kit (Qiagen), 
350 µl of buffer RTL was added to the diluted sample and mixed well. Then 250 µl 
of 95% ethanol was added, mixed and the mixture was transferred onto a column 
provided in the kit and centrifuged for 20 seconds at full speed. The sample was 
then washed twice with the RPE wash buffer and centrifuged for 1 minute in a new 
tube to remove excess of buffer. The RNA was then eluted with 50 µl of nuclease-
free water. Aliquots of 50 ng/ µl in 5 µl were stored at -80 ºC until injection.  
4.3.3 Electron microscopy of zebrafish embryos 
Fish were sedated in MS222 and fixed overnight in 2% formaldehyde, 2.5% 
glutaraldehyde in wash buffer (0.1 M Sodium Cacodylate Buffer pH 7.4). Samples 
were then washed and incubated for 2 hours in 1% Osmium Tetroxide in wash 
buffer. Following a wash, samples were dehydrated in 10%, 25%, 50%, 70%, 90%, 
95%, 100% ethanol for 10 minutes and washed twice with 100% propylene oxide. 
Samples were then washed in increasing concentration of low viscosity epoxy resin 
at 25% for 3 hours, then 50% overnight, 75% twice 2 hours, finally embedded in 
100% overnight then placed in the oven at 60ºC for 48 hours. 
Linearised DNA          1 µg
10x reaction buffer            2µl
2x dNTPs 10 µl
T7 enzyme                         2µl
H2O                                    …
TOTAL VOLUME            20 µl
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4.3.4 Fluorescent in situ hybridization on frozen zebrafish sections 
Embryos were sedated in MS222 and fixed in 4% PFA for 2 hours at room 
temperature. They were then dehydrated in methanol and stored at -20 ºC.  
Embryos were rehydrated in descending concentrations of methanol in PBS 90%, 
75%, 50%, 25%, followed by a few PBS washes. They were then embedded in 
25% cold water fish gelatine (Sigma), 15% sucrose at room temperature for 24 
hours. Samples were frozen on dry ice and 8 µm sections were cut with a Cryosta 
Leica CM 3050S at -20 ºC, collected on pre-coated poly-lysine slides (VWR) and 
stored at -80 ºC.  
Frozen sections of 5dpf embryos were taken out of the -80°C freezer, left to dry 
and dipped into acetone for 2 minutes before being rehydrated in PBS. Samples 
were treated with 10 µg/ml protease K (Bioline) for 10 minutes, rinsed in PBS then 
fixed in 4% PFA for 20 minutes. Samples were then washed with PBS and washed 
twice for 10 minutes with 2xSSC (Standard Sodium Citrate)(Table 2.1)/10% 
formamide (Sigma). The in situ hybridization protocol was adapted from Rouquette 
et al. (Rouquette et al. 2005). The hybridization was performed at 37ºC for 3 hours 
in the following buffer: 10% formamide, 10% dextran sulphate (Millipore), 2xSSC, 
0.5 mg/ml tRNA (Sigma), 50 mg/ml BSA (Bovine serum albumin-Sigma) and 
10mM ribonucleosidevanadyl complexes (NEB UK) containing 10 ng/ml of Cy2 
tagged probe (Invitrogen). The slides were then washed twice with 2xSSC/10% 
formamide, once with PBS and then mounted with DAPI (Vector Labs). 
Images were collected on a Leica TCS SP5 AOBS inverted confocal using a 40x 
objective. When acquiring 3D optical stacks the confocal software was used to 
determine the optimal number of Z sections. Only the maximum intensity 
projections of these 3D stacks are shown in the results. 
4.3.5 RNASET2 knockdown in HEK 293 cells 
A custom-designed miRNA targeting RNASET2 as well as a control miRNA, both 
based on the hairpin structure of mouse miR30a (Nicoli, Standley et al. 2010) but 
with the targeting sequences (underlined in the following sequences) against 
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human RNASET2 selected using BLOCK-iT™ RNAi Designer 
(https://rnaidesigner.invitrogen.com/rnaiexpress/), were generated by using the 
following program and the following oligonucleotides: 
Reaction program: 
 
 
 
 
 
Sequences: 
Control miRNA forward: 5′- 
GCGGGGTACCGCGGGGATCCTGCTGTTGACAGTGAGCGA 
TTCTGGAAGCATGAGTGGGAATAGTGAAGCCACAGATG -3′ 
Control miRNA Reverse: 5′- 
CCGCGAATTCCCGCAGATCTCCTTGAAGTCCGAGGCAGTAGGCAG 
TTCTGGAAGCATGAGTGGGAATACATCTGTGGCTTCAC -3′ 
RNASET2 miRNA forward: 5′- 
GCGGGGTACCGCGGGGATCCTGCTGTTGACAGTGAGCGA 
AAGCCAGGATGAGGAAGTACATAGTGAAGCCACAGATG -3′ 
RNASET2 miRNA reverse: 5′- 
CCGCGAATTCCCGCAGATCTCCTTGAAGTCCGAGGCAGTAGGCAG 
AAGCCAGGATGAGGAAGTACATACATCTGTGGCTTCAC-3′ 
The resultant PCR product was digested with KpnI and EcoRI, subcloned into P-
GEMT (see 2.2.5) and finally cloned into the intron of an EF1α-intron-cherry 
plasmid construct [comprising the promoter, non-coding exon I and intron I of the 
zebrafish EF1alpha gene spliced with cDNA encoding cherry fluorescent protein 
(Appendix, Figure 4)] as previously described (Nicoli, Standley et al. 2010). 
Hot lid 110°C
Denature 96ºC for 5 minutes
Denature 95ºC for 20 seconds
Anneal 37ºC for 20 seconds                    9 cycles
Elongation 68ºC for 10 seconds
Elongation 68ºC for 5 minutes
Store at 4°C
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HEK 293 cells were transfected with 800ng of miRNA plasmid using Fugene 
(Roche) as instructed by the manufacturer. Western blotting with a rabbit 
polyclonal human RNASET2 anti-serum (1:500) and a secondary anti-rabbit 
antibody (GE Healthcare UK) was used to demonstrate knockdown (Henneke et al. 
2009). 
4.3.6 Electron microscopy of HEK 293 cells 
Cells were trypsinised and pelleted, then washed with PBS and pelleted again. Half 
of the supernatant was taken off then the same volume of double strength fixative 
was added (5% glutaraldehyde in 0.2M Sodium Cacdylate Buffer pH 7.4). Cells 
were fixed overnight at 4°C and centrifuged for 15 minutes at 5000g then kept as a 
pellet. The pellet was washed 3 times in 0.1 M sodium cacodylate buffer pH7.4 and 
incubated in 0.1M Osmium Tetroxide in 0.1 M Sodium Cacodylate buffer pH 7.4 
for 2 hours. The pellet was washed 3 times in 0.1 M sodium Cacodylate buffer pH 
7.4 then 3 times in dH2O. It was then incubated in 0.1% Uranyl Acetate in dH2O 
for 1 hour and washed again 3 times in dH2O. This was followed by dehydration 
through ethanol series (25%, 50%, 70%, 80%, 90%) for 10 minutes each and 3 
times 10 minutes in 100% etanol. The pellet was then quickly rinsed 3 times in 
propylene oxide and washed in increasing concentrations of low viscosity epoxy 
resin medium 25%, 50%, 75%. Finally, the cell pellet was washed 3 times with the 
resin and embedded overnight at 60ºC. 
For both zebrafish and human samples, ultra-thin sections (70-80 nm) were cut 
using a Reichert Jung Ultramicrotome. Observations were carried out using a FEI 
Tecnai12 BioTwin microscope and photographs were taken using a 4k x 4K CCD 
camera (Eagle, FEI Company) equipped with Kodak 4489 film. Images were 
acquired using an Imacon scanner and FlexColor software. 
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4.3.7 Live cell imaging with LysoTracker 
HEK 293 cells were stained with 5µM of the intravital dye Green LysoTracker 
(Invitrogen) for 20 minutes at 37ºC with 5% CO2. Cells were then trypsinised and 
the fluorescence was analysed by flow cytometry. 
4.3.8 Magnetic resonance imaging 
Animals were fixed in the laboratory and send to A. Alia at the chemistry 
department of Leiden University, The Netherlands for the MRI analysis. 
Adult zebrafish were sedated in MS222 and fixed in 4 % buffered PFA for 2 days 
and subsequently embedded in Fomblin. All µMRI measurements were conducted 
on a 400 MHz (9.4T) vertical bore system, using a transmit/receive birdcage 
radiofrequency coil with an inner diameter of 10 mm and a 1 Tm-1gradient insert 
from Bruker Analytic, Germany. The system was interfaced to a Linux operating 
system running Topspin 2.0 and Para Vision 5.0 imaging software (Bruker Biospin, 
Germany). Before each measurement the magnetic field homogeneity was 
optimized by shimming. Each session of measurements began with a multislice 
orthogonal gradient-echo sequence for position determination and selection of the 
desired region for subsequent experiments. For high resolution, T2-weighted MR 
images were acquired by a rapid acquisition with relaxation enhancement (RARE) 
sequence  which employs a single excitation step followed by the collection of 
multiple phase encoded echoes (Henning, Nauerth et al. 1986). Basic measurement 
parameters used for the RARE sequence were: echo time (TE) = 10.567 ms (22.45 
ms effective), repetition time (TR) = 5 s, flip angle = 90 °, averages = 64, RARE 
factor (echo train length) = 4. The field of view was 1.2 x 1.2 cm2, with image 
matrix of 256 x 256. This yields an effective in plane resolution of approximately 
47 µm. Horizontal and sagittal image slices (20) were acquired with slice thickness 
of 0.2 mm spaced 0.2 mm between slices. For T2 relaxation time measurement, a 
multislice multi echo (MSME) sequence was used. Imaging parameters were: FOV 
2.0 x 2.0 cm2, matrix size 256 x 256, number of averages 2, number of slices 6 with 
slice thickness of 0.5 mm, number of echos 12 with TE of 8.5, 17.0, 25.5, 34.0, 
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42.5, 51.0, 59.5, 68.0, 76.5, 85.0, 93.5, 102.0 ms and a repetition time of 1.5 s . For 
calculation of T2 relaxation time, regions of interest (ROIs) were drawn at various 
locations within the brain. Means and standard deviation for T2 relaxation times for 
each ROI were calculated. 
4.3.9 Immunohistochemistry 
The mouse anti-amyloid protein precursor (APP) from ZYMED was used at 1:500. 
And the mouse anti-glial fibrillary acidic protein (GFAP) from DAKO was used at 
1:300. Images were taken on a Leica DM LB2 equipped with a Leica camera and a 
Leica application suite software. 
4.3.10 Whole mount in situ hybridization of zebrafish embryos 
Embryo development was monitored until the mid-hindbrain boundary was formed 
(28hpf) and were then fixed in 4% PFA in PBS at 4 ºC. After overnight fixation, 
PFA was removed and samples were washed with PBST a few times. All washes 
were done at room temperature for 5 minutes, except when specified. Samples 
were then washed in methanol twice and placed at -20 ºC for 30 minutes (at this 
stage, samples can be stored for months). Embryos were then rehydrated in 
increased concentrations of PBST in methanol: 75%, 50%, 25%, and finally 
washed in PBST twice. To help permeabilisation, embryos were incubated in 30 
µg/ml protease K (Bioline) in PBST for 8 minutes. The reaction was stopped by 
adding 2 mg/ml of glycine (Sigma) in PBST for 5 minutes. Samples were then re-
fixed in 4% PFA for 20 minutes at room temperature and washed twice in PBST. 
Samples were then briefly washed in 50% PBST/50% hybridization buffer (HB) 
[50% deionized formamide (Sigma), 5x SSC (Table 2.1), 500 µg/ml yeast RNA 
(Boehringer Mannheim), 50 mg/ml heparin (Sigma), 0.1% Tween 20 (Sigma), pH6 
with 1 M citric acid (Broadbent and Read 1999)] and followed by 1 hour of 
incubation in HB at 65 ºC. The probe was then added to the HB at 1:500 and 
samples were incubated overnight a 65 ºC. The probes Fgf3, Hoxb1a, and Pax2.1 
used to stain the midbrain, the rombomere 4 of the hindbrain, and the mid brain 
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boundary respectively (Krauss, Johansen et al. 1991; Sleptsova-Friedrich, Li et al. 
2001; Rohrschneider, Elsen et al. 2007). The pcGlobin 2 vector [Appendix, Figure 
5 (Ro, Soun et al. 2004)] was linearised as described in 4.3.2 and the mRNA was 
created using DIG RNA labeling kit (Roche) following the manufacturers 
instructions. The mRNA was processed and injected the same way than already 
described in 4.3.2. 
After incubation, the probe was removed and store at -20 ºC for reuse and the 
samples underwent the following washes (Table 4.1). Samples were then blocked 
for 1 hour at room temperature in 5% FCS (Fecal calf serum) with 10 mg/ml of 
BSA in PBST. This solution was replaced with 1:1000 anti-Dig-AP antibody 
(Roche) diluted in 2mg/ml of BSA in PBST and incubated overnight at 4 ºC on 
gentle shaking. Samples were then washed 8 times 15 minutes in PBST, then 
equilibrated 3 times 5 minutes in staining buffer (NTMT- 1 ml 1 M Tris pH 9.5, 1 
ml 1 M NaCl, 0.5 ml 1 M MgCl2, 0.1% Tween 20 in 7.5 ml of MilliQ H2O). 
Finally, the colour reaction [200 µl of the NBT enzyme/X-phosphate-BCIP 
substrate (Roche) in 10 ml of NTMT] was added to the samples and incubated at 
37 ºC until appearance of the staining. The reaction was stopped in PBST with 
20mM EDTA, and background staining was removed by a 10 minutes methanol 
wash. Samples were then fixed in 4% PFA for 30 minutes and stored in 80% 
Glycerol (Sigma) in PBS. Pictures were taken on a Zeiss LumarV12 microscope 
equipped with an AxioCamera and the AxioVision software. 
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Number Duration/Temperature Buffer 
3 10 minutes/ 65 ºC 50% HB/50% 2x SSC 
1 10 minutes/65 ºC 2x SSC with 0.1% Tween-20 
4 10 minutes/65 ºC 0.2x SSC with 0.1% Tween-20 
1 5 minutes/Room temperature 
75% 0.2 SSC/25% 
PBST 
1 5 minutes/Room temperature 
50% 0.2 SSC/50% 
PBST 
1 5 minutes/Room temperature 
25% 0.2 SSC/75% 
PBST 
1 5 minutes/Room temperature PBST 
 
Table 4.1: Details of the different washes used in the in situ hybridization 
protocol 
 
 
4.4 Results 
4.4.1 Mutation in the rnaset2 gene results in an increase of acridine 
orange uptake  
As described in chapter III, a STOP codon was found within codon 118 of the 
rnaset2 open reading frame. Rnaset2 possesses 9 exons, with a signal peptide and 2 
catalytic domains, the latest being highly conserved among other species (Figure 
4.1 A-B). This STOP codon resulted in the truncation of half of the protein before 
its conserved catalytic site CAS II (Figure 4.1 B). A dramatic down-regulation of 
the rnaset2 message in the mutant was shown by RT-PCR (Figure 4.1 C), 
presumably through nonsense mediated decay (Chang, Imam et al. 2007), therefore 
confirming that the mutation in rnaset2 was a loss of function mutation. 
An easy assay was developed to quantify the difference in AO uptake: embryos 
were treated with AO and dissociated into a single cell suspension. The 
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fluorescence was then assessed by flow cytometry which revealed an increased 
fluorescence signal in the mutant sample (Figure 4.2). 
This assay was used in the rescue and morpholinos knockdown experiments to 
confirm that the mutation in rnaset2 was responsible for the observed phenotype. 
Messenger RNA (mRNA) was produced from full-length wild type rnaset2 cDNA 
and injected at 25ng/µl into one cell stage mutant embryos. Flow cytometry 
analysis confirmed restoration of normal AO staining in rnaset2 injected embryos 
(Figure 4.3 C) similar to the wild type signal (Figure 4.3 B). In contrast, injection 
with a mutant version rnaset2T304A created by site directed mutagenesis did not alter 
AO staining (Figure 4.3 C) and displayed a comparable phenotype to mutant 
AO127 (Figure 4.3 B). This finding implies that the observed rnaset2 mutation is 
indeed responsible for the AO phenotype. 
To knock down rnaset2 in wild type zebrafish, a splice Morpholino (MO) was 
designed against exon 3 of rnaset2 (Figure 4.3 A) and was injected in the yolk of 
heterozygote embryos at the first cell stage. RT-PCR confirmed the splicing of 
rnaset2 in splice MO injected embryos with a higher DNA band (Figure 4.3 D) 
which, upon sequencing, revealed retention of the intron 4 (data not shown). Flow 
cytometry analysis showed that splice MO injected embryos did not reproduce the 
exact same phenotype than mutant but an increase in fluorescence was still 
observed compared to the control MO (Figure 4.1 D). This might be explained by 
some non spliced wild type product still present as shown by the RT-PCR in figure 
4.1 D. 
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Figure 4.1: rnaset2 mutation. Structure of the zebrafish rnaset2 Dre2 gene. Exons 
are represented as boxes and intron as lines. The shaded areas represent 
untranslated regions, comprising the 5’ and 3’ UTR regions [adapted from Hillwig 
2009 (Hillwig, Rizhsky et al. 2009)] (A). rnaset2 protein alignment to show 
conservation of the catalytic domains CAS I and CAS II and the signal peptide 
among orthologues in other species (black square). Location of the mutation (black 
arrow) before the conserved catalytic site CAS II (B). RT-PCR showed down 
regulation of rnaset2 message in the mutant sample (C). 
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Figure 4.2: Acridine orange assay. To quantify the difference in fluorescence 
between mutant and wild type, stained embryos were dissociated and analysed by 
flow cytometry. The mutant showed a stronger signal compared to the wild type. 
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Figure 4.3: Rescue and morpholinos knockdown experiments. Flow cytometry 
quantification was performed on dissociated 3dpf embryos previously stained with 
AO. Schematic of the zebrafish rnaset2 gene showing exon-intron structure and the 
position of the MO to splice exon 3 (A). Quantification of the difference of 
fluorescence between mutant and wild type samples (B). The mutant AO127 
phenotype was rescued by injection of wild type rnaset2 unlike the control using 
mutant ∆rnaset2T304A. RT-PCR showed that low expression of rnaset2 in the 
rnaset2 rescued sample is sufficient to rescue the phenotype (C). Injection of splice 
MO but not control MO in heterozygous animals resulted in an increase in AO 
staining. The splicing was confirmed by RT-PCR with presence of a retained intron 
in the MO injected samples (D). 
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4.4.2 rnaset2 deficient zebrafish suffer from a lysosomal storage 
disorder 
As discussed in the introduction, deficiencies of lysosomal hydrolases are 
frequently associated with the appearance of engorged lysosomes. AO is a 
basophilic intravital dye that preferentially stains lysosomes; thus increased AO 
staining could indicate supernumerary or enlarged lysosomes. To test this, sections 
of 5dpf embryos were examined using electron microscopy. Electron dense 
materials were readily apparent in the brain of mutant embryos, while they were 
absent in wild-type siblings (Figure 4.4). The density and morphology of these 
vesicles suggest that the mutant samples have enlarged lysosomes. In situ 
hybridization identified the content of the enlarged lysosomes: ribosomal RNA 
(rRNA) was shown to accumulate in lysosomes of rnaset2 deficient embryos 
(Figure 4.4) using a 28S rRNA antisense probe. The sense probe was used as a 
control and showed a lower signal (Appendix, Figure 6). 
 
To confirm these findings in cells of human origin, different miRNAs were 
designed against the human RNASET2 gene and cloned into a plasmid where 
miRNA expression is driven by the Ef1alpha protein and linked to expression of a 
cherry reporter gene to be transfected into HEK 293 cells. The knock down 
efficiency was assessed by RT-PCR for miRNA1 and miRNA2; miRNA1 did not 
produce any down regulation of the message compared to miRNA2, even 3 days 
after transfection (Appendix, Figure 7). miRNA2 was then used to knock down 
RNASET2 in cells and miRNA1 was used as a control.  After checking the 
efficiency of the knock down at the protein level by western blotting using miRNA 
compared to the control (Figure 4.5 A), fluorescent acidotropic probe LysoTracker 
Green (Invitrogen) was used to detect changes in acidic compartments such as 
lysosomes. Flow cytometry reported a significant increase of fluorescence in cherry 
positive knocked down HEK 293 cells (Figure 4.5 B). EM was performed on these 
cells to visualise the difference in lysosomes. Contrary to what was expected, the 
cells lacking RNASET2 did not present any large lysosomes as previously seen on 
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fish sections, but the number of lysosomes appeared to be more abundant (Figure 
4.5 C). Furthermore, quantification of the EM sections by counting the number of 
lysosomes per grid showed that the number of lysosomes was 5 times higher in 
knock down cells compared to controls (Figure 4.5 D). 
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Figure 4.4: Mutant brains present large lysosomes full of undegraded rRNA. 
Brain cross sections from 5 dpf embryos (n=3) analysed by EM revealed electron 
dense vesicles, resembling enlarged lysosomes in the zoomed area, in neurons from 
mutants only (red arrows, scale bars = 5µm). In situ hybridization on brain cross 
sections (n=3) using a 28S rRNA probe identified the content as undigested rRNA 
(white arrow, scale bar= 10µm).  
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Figure 4.5: Increased number of lysosomes in RNASET2 knock down HEK 
293 cells. The knock down of RNASET2 by miRNA was assessed by western blot 
(A). The lysosome marker LysoTracker was used to assess the difference in 
lysosomes by flow cytometry. The fluorescence signal was two fold higher in the 
knock down cells compared to the control (B) and an increase in lysosome number 
was visible by EM (red arrows, C) (cyt= cytoplasm, scale bar= 1µm). 
Quantification by counting the number of lysosomes per grid of the EM section 
showed a 5 fold increase in knock down cells (D). 
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4.4.3 Neurodegeneration in rnaset2 deficient zebrafish 
As previously described, MRI identified abnormalities in the brain of RNASET2 
deficient children (Henneke, Diekmann et al. 2009). To address whether rnaset2 
deficient zebrafish displayed the same anomalies, T2-weighted Magnetic 
Resonance microImaging (µMRI) was also performed by our collaborators at the 
University of Leiden, The Netherlands to analyse adult zebrafish (Kabli, Alia et al. 
2006). White matter lesions adjacent to brain ventricles were observed on sagittal 
and coronal sections of all mutant animals analysed (Figure 4.6). While cortical 
cysts were not apparent, ventricles in mutants appeared more dilated compared to 
wild types (Figure 4.7). The use of another MRI technique, analysis of T2 
relaxation time, suggested that the white matter lesions might be filled with fluid 
similar in composition to cerebrospinal fluid in ventricles (Figure 4.8). 
To further characterise these lesions, immunohistochemical staining using 
neurodegeneration markers was performed on adult zebrafish brain sections. 
Staining with an antibody recognizing Amyloid precursor protein (APP) indicated 
APP accumulation around the ventricles of mutant brains and thus possible axonal 
damage (Figure 4.9)(Suenaga, Ohnishi et al. 1994). Likewise, staining for glial 
fibrillary acidic protein (GFAP) revealed an increase of astrocytes evident in white 
matter regions bordering ventricles suggesting an increase of inflammation (Figure 
4.9). 
It is important to note that animals deficient for rnaset2 appeared overtly normal 
without obvious motor deficiencies, reached a normal adult size and weight, and 
were fertile (Appendix, Figure 7). Even brain morphology was similar, and no 
difference was visualised by performing in situ hybridization for markers of 
different brain regions (Appendix, Figure 8). 
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Figure 4.6: µMRI on adult zebrafish brain revealed abnormalities: µMRI 
identified white matter lesions in the forebrain on sagittal sections (A) and in the 
telencephalon on coronal sections (B) of mutant fish only (n=7). No lesions were 
visible in WT (n=3). Scale bar=1mm. 
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Figure 4.7: Presence of dilated ventricles in mutant brain. Coronal sections on 
µMRI revealed dilated ventricules in mutant brains (n=7) compared to wild type 
(n=3). Scale bar=500µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: White matter lesions are filled with cerebrospinal fluid. T2 
relaxation time comparing the brightness of the staining between damaged (number 
3,4,5) and healthy area (1,2) suggested that the white matter lesion (white arrows) 
were filled with fluid similar to the fluid present in ventricles. Scale bars= 1mm. 
1
3
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5
Area        T2 relaxation time 
(ms)
1 28.3±1.02
2 25.01±1.26
3 31.09±1.31
4                32.14±0.99
5                33.7±1.04
WT mutant
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Figure 4.9: Axonal damage and increased inflammation in mutant brains. 
Immunohistochemistry on sections of adult brain were stained with the APP and 
GFAP antibody and showed a greater staining in the mutant sample (Scale bars= 
100µm). 
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4.5 Discussion 
 
So far the rnaset2 deficient zebrafish mutant is the first zebrafish mutant available 
to study LSDs. Transient morphants reproducing the human mucolipidosis II 
disease were described very recently by using morpholino knock down (Flanagan-
Steet, Sias et al. 2009). Mucolipidosis II is an LSD caused by a defective enzyme 
responsible for tagging lysosomal hydrolases in order to lead them to the 
lysosomes. These enzymes were found to go to the extra cellular matrix instead, 
leading to accumulation of undigested substrate in lysosomes (Kornfeld and 
Mellman 1989; von Figura 1991). Feline and murine models for this disease 
reproduced the symptoms observed in patients, but early development defects 
cannot be analysed due to the intrauterine gestation (Mazrier, Van Hoeven et al. 
2003; Gelfman, Vogel et al. 2007). The morpholino (MO) model that Flanagan-
Steet et al generated gave a valuable insight into developmental impact of the 
mucolipidosis II, but MOs give only a transient knock down with various 
efficiencies (Nasevicius and Ekker 2000). The rnaset2 mutant will allow 
investigation of the disease not only during the first 3 days of development, but 
during the entire life of the animal to identify the causes of the pathology and 
potential treatment. 
 
This study showed that zebrafish lacking rnaset2 accumulated undigested rRNA in 
their neurons, which over time, created brain damage with white matter lesions 
showing axonal damage and increased inflammation. The similarities of lesions 
found between zebrafish and human demonstrated that the leukoencephalopathy 
observed in RNASET2 deficient children resulted from an LSD. As mentioned in 
chapter 4.1, LSDs generally cause neurodegeneration. The Niemann-Pick type C 
disease (NPC) displayed neuronal storage throughout the brain and affected 
children suffered from dementia and ataxia (Pentchev, Vanier et al. 1995). Some 
diseases showed very selective phenotype. For example, there is no storage seen in 
neurons in the Gaucher disease but only in the Gaucher cells, derived from the 
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macrophage lineage (Beutler and Grabowsky 2001). Puzzles and clues are solved 
every day about LSDs, but the main question is how storage of undigested 
substrate can lead to pathology? 
The accumulation of unmetabolised substrates in lysosomes is the primary cause of 
the disease. The tissue affected is usually where the undigested substrate is needed 
the most, rRNA in the brain for RNaseT2 deficiency in zebrafish and human, or as 
already mentioned in the 4.1, glycogen in the Pompe disease accumulating in 
muscles (Hirschhorn and Reuser 2001). But for most of the LSDs, the range of 
symptoms is wide and might indicate the activation of secondary intracellular 
pathways, which are so far unknown. 
 
A lack of rnaset2 in zebrafish resulted in accumulation of undigested rRNA 
therefore suggesting a physiological role for rnaset2 to specifically recycle 
ribosomes. Selective autophagy for various organelles was described in different 
organisms. Previously in yeast, a specific autophagy for ribosomes was described; 
upon starvation, mature ribosomes were selectively degraded by an autophagic 
process called ribophagy (Kraft et al. 2008). Moreover, studies in Arabidopsis with 
RNS2, the only intracellular plant homologue of human RNASET2, showed a 
doubled half-life of rRNA in RNS2 deficient plants (M. Hillwig and G. MacIntosh-
unpublished). 
During starvation in yeast, it is suggested that ribophagy limited protein translation 
and ribosome biogenesis, both very energy consuming for the cell (Kraft, Deplazes 
et al. 2008). So potentially, impaired ribophagy in rnaset2 deficiency can lead to 
translational defects. 
 
The substrate itself leading to cytotoxicity could be another hypothesis. Mutation in 
another ribonuclease, RNASEH2, lead to a very similar leukoencephalopathy 
(Crow, Leitch et al. 2006). RNASEH2, however, is not a lysosomal enzyme and its 
role is to cleave DNA:RNA hybrids found in the Okasaki fragments (Qiu, Qian et 
al. 1999). Additionally in Alzheimer disease, rRNA provides a binding site for 
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redox-active iron, a potent source of harmful reactive oxygen species within the 
cytoplasm of vulnerable neurons (Honda, Smith et al. 2005). 
When accumulation of cytotoxic products triggers cell death, the clearance system 
is activated to remove damaged neurons. Most LSDs and neurodegenerative 
disorders exhibit an increase in the inflammatory response with an activation of 
microglia. Similarly to rnaset2 deficient zebrafish, Sandhoff disease mice presented 
neurodegeneration with activation of microglia activity (Wada, Tifft et al. 2000). 
The increased activity of microglia can result from inappropriate intrinsic cell 
signalling due to potential substrate storage or an appropriate response due to 
presence of damaged neurons (Walkley 2009). Either way, microglia activation is a 
sign of neuron abnormalities and should be further studied. 
 
Additionally, knock down of RNASET2 experiments in HEK 293 cells showed a 
greater number of lysosomes, suggesting an increase in lysosome biogenesis. 
Increased lysosome biogenesis and activation of the autophagic components have 
previously been described as a compensatory mechanism in neurodegenerative 
diseases and ageing related deficits (Butler, Nixon et al. 2006). In Hungtington’s 
disease, the lysosomal cathepsin D was found to be activated by the huntingtin 
fragment, thereby aiding the clearance of the accumulated structures (Qin, Wang et 
al. 2003). Activation of Cathepsin D was also observed in pyramidal neurons of 
Alzheimer’s brain (Cataldo, Barnett et al. 1997). The role of autophagy was also 
studied in LSDs, and a strong correlation was discovered between autophagy 
regulation and storage. 
Activation of autophagy in some LSDs was found by looking at the level of Beclin-
1, which is activated during autophagy induction. The Pompe disease mouse model 
showed an induction of the autophagy pathway (Fukuda, Ewan et al. 2006). The 
same was shown in a mouse model for the NPC disease and Neuronal Ceroid-
Lipofuscinose (NCL) (Ko, Milenkovic et al. 2005; Koike, Shibata et al. 2005). On 
the contrary, other LSDs, such as Danon disease and Multiple Sulphtase Deficiency 
(MSD), showed a block of autophagy with evidence of impaired autophagosome-
lysosome fusion and also accumulation of other substrates such as aberrant 
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mitochondria (Tanaka, Guhde et al. 2000; Settembre, Fraldi et al. 2008; Ballabio 
and Gieselmann 2009). The leading hypothesis is that LSDs prevent lysosomes 
from performing their role in autophagy. They are engorged with undigested 
substrates that affect the fusion with autophagosomes, resulting in a partial block of 
autophagy. As mentioned before, a compensatory mechanism will then induce 
autophagy, by Beclin-1 activation, to overcome the blockage (Ballabio and 
Gieselmann 2009). Therefore, LSDs can lead to autophagic disorders that will 
aggravate the primary storage, as a block in autophagy results in accumulation of 
secondary substrates, and will be involved in the pathology process. A possible 
therapeutic strategy would be to use activators of the autophagy pathways to avoid 
secondary accumulation on top of the storage disorder. 
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Chapter V: RNaseT2 and Cancer 
 
5.1 Introduction 
Work performed by the Taramelli laboratory was the first to establish a link 
between RNASET2 and cancer. Abnormalities of the chromosome region 6q27 
have been linked to various solid cancers such as carcinomas of the ovary (Saito, 
Saito et al. 1992), uterus (Tibiletti, Bernasconi et al. 1996), stomach (Queimado, 
Seruca et al. 1995), melanoma (Millikin, Meese et al. 1991) and many more.  
RNASET2 is located between markers D6S193 and D6S297 in the critical interval 
of chromosome 6 deleted in ovarian carcinomas (Tibiletti, Trubia et al. 1998). The 
Taramelli laboratory mapped, cloned and characterised RNASET2 as a tumour 
suppressor gene inducing senescence and being down regulated in ovarian 
carcinoma cell lines (Acquati, Morelli et al. 2001). Subsequent work from this 
group also revealed that administration of recombinant RNASET2 could improve 
the survival of mice bearing ovarian metastases, imputing antitumourigenic and 
antimetastatic activities to this ribonuclease (Acquati, Possati et al. 2005). 
RNASET2 was also found to synergise with Paclitaxel in treatment against colon 
cancer cells implanted in mice (Smirnoff, Roiz et al. 2006). Furthermore, tumour 
sections revealed a decrease in angiogenesis in the RNASET2 treated mice, 
imputing also antiangiogenic properties to RNASET2 (Smirnoff, Roiz et al. 2006). 
Similar effects were shown for ACTIBIND, a fungal RNaseT2: treatment with 
ACTIBIND reduced the size of xenografted colon tumours implanted in mice and 
also inhibited angiogenesis in human umbilical vein endothelial (HUVE) cells 
(Roiz, Smirnoff et al. 2006). Finally ACTIBIND was shown to inhibit melanoma 
growth in vivo in mice innoculated with the highly metastatic cell line A375SM 
(Schwartz, Shoseyov et al. 2007). 
Many tools are available in zebrafish to further interrogate the role of rnaset2 in 
tumorigenesis. As mentioned in Chapter I (1.3.3), many zebrafish cancer models 
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are accessible and previous work in our laboratory created a zebrafish melanoma 
model. This transgenic line has a constitutively active human HRas (V12HRas or 
simply V12Ras) driven by a melanocyte specific promoter (mitf) and develops 
spontaneous malignant melanoma (Michailidou, Jones et al. 2009). Zebrafish also 
offers great advantages to look at angiogenesis, its development ex-utero and its 
transparency allow direct visualisation of angiogenesis in the intestinal basket 
using the alkaline phosphatase assay as a vasculature stain (Nicoli and Presta 
2007). The Fli1-GFP transgenic line, in which GFP is expressed into the 
vasculature, also allows visualisation of new vessel formation and interaction 
between tumour cells and the vasculature (Stoletov, Montel et al. 2007). 
Thus, establishing a transgenic V12Ras line in which rnaset2 was deficient and 
analysing blood vessel formation in early embryos would provide an insight into 
the role of rnaset2 in tumourigenesis and angiogenesis. 
 
5.2 Aim 
Use in vitro and in vivo tools to assess whether or not the ribonuclease T2 behaves 
as a tumour suppressor in melanoma and as an inhibitor of angiogenesis in 
zebrafish. 
 
5.3 Materials and methods 
5.3.1 Melanoma cell line culture 
HEM-nMP are normal human melanocytes and were cultured in Medium 254 
(Invitrogen) with 1% of Human Melanocyte Growth Supplement HMGS 
(Invitrogen). The established melanoma cell lines MV3, WM981, WM1158, 
WM1341B, SKMel2, WM2664, WM852 and WM9 were all cultured in complete 
DMEM (see Table 2.1). 
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5.3.2 RT-PCR on zebrafish samples 
Adult zebrafish were sedated in ice cold water and decapitated under schedule 1 
regulation. Tumours were sectioned with a clean scalpel and placed in a clean 
eppendorf tube. Samples were then immediately frozen in liquid nitrogen and 
stored at -80°C until RNA extraction (see Chapter II, 2.4.1). For skin tissue 
samples, animals were skinned with forceps and the skin was handled the same 
way than the tumours. cDNA was synthetised as described in Chapter II (2.4.2) and 
the primers used for the RT-PCR are listed below: 
To look at rnaset2 at the message level, 55°C annealing temperature for 30 cycles: 
rnaset2 forward: 5’-GGCCAGATCTGCTAGAACC-3’ 
rnaset2 reverse: 5’-ATGCCAAGATGTGTTGCACC-3’ 
For a loading control, 55°C annealing temperature for 25 cycles: 
Ef1α forward: 5’-CGCACAGTAACACCGAAAC-3’ 
Ef1α reverse: 5’-TCAAACTCACCCACACCAC-3’ 
5.3.3 Genotyping 
5.3.3.1 DNA extraction from fin clips 
Adult fish were sedated as described in Chapter II (2.3.4) and caudal fin tissue 
from adult was amputated with a clean scalpel for genotyping purposes. 
The caudal fin-clips isolated from individual fish were incubated overnight at 62 ºC 
in 380 µl of DNA lysis buffer (see Table 2.1) and 20 µl of 10 mg/ml proteinase-K 
(Bioline) to lyse the tissue. An equal volume of isopropanol was then added and the 
samples were inverted 6 -10 times until the DNA precipitated. Samples were then 
centrifuged at 13,000g for 15 minutes, the supernatant was discarded and the 
pelleted DNA was washed with 1 ml of 70% ethanol and pelleted again at 13,000g 
for 10 minutes. The DNA pellet was left to air dry and was finally resuspended in 
50 µl of TE buffer pH 8. Isolated genomic DNA was either used immediately for a 
nested PCR or stored at -20ºC.  
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5.3.3.2 Nested PCR 
A first PCR was run as described in 2.2.1 using 5µl of DNA extracted from fin 
clips using the following primers: 
Forward 3’-GACATACTACCAGAAATGG-5’ 
Reverse 3’-GGTCAAACTTGTGGTAGAGTTCG-5’ 
A second nested PCR was run using 2µl of the DNA from the previous PCR with 
the following primers: 
Forward 5’-GGCCAGATCTGCTAGAACCA-3’ 
Reverse 5’-GACTCTGATTTTGCAGCACAGG-3’ 
The annealing temperature was 55 ºC with 30 cycles for both PCRs. The nested 
PCR was performed in order to saturate the amount of DNA to produce enough 
material for a digest. 
5.3.3.3 Digest 
The DNA bands were cut out from the PCR gel and purified as described in 2.2.3. 
A digest using the MseI restriction enzyme (New England Biolabs) was then set up 
with 10µl of DNA from the nested PCR. The digest was run on a 2% gel and 
analysed. 
5.3.4 Tumour assay 
Wild type and mutant zebrafish crossed to the V12Ras line were observed every 
month for presence of tumours. Fish with tumours were separated from the rest, 
and sedated as described in Chapter II (2.3.4) and the tumours were measured once 
a week with a digital calliper (World precision Instruments) as described in figure 
5.1. 
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Figure 5.1: Digital calliper used to measure tumour size. 
 
5.3.5 Alkaline phosphatase assay 
70hpf embryos were fixed in 4% PFA overnight at 4ºC. After fixation, they were 
washed twice in PBS for 5 minutes and incubated in acetone at -20ºC for 20 
minutes. Samples were then washed twice in PBS for 10 minutes, from now until 
specified, all washes are done for 10 minutes on a rotator. Samples were 
dehydrated in increasing concentrations of ethanol in PBST, 50%, 66%, 75% and 
100%. Samples were then rehydrated in increasing concentrations of TT buffer (1 
M Tris pH 9.5, 0.1% Tween-20) in ethanol, 33%, 50%, 66% and 100%. Samples 
were equilibrated in NTMT buffer (1 ml 1 M Tris pH9.5, 1 ml 1 M NaCl, 0.5 ml 
1M MgCl2, 0.1% Tween-20 in 7.5 ml of MilliQ H2O) and incubated with 1 ml of 
NTMT buffer with 16.9 µl of 20 mg/ml NBT enzyme (Sigma) and 3.5 µl of 50 
mg/ml X-phosphate/BCIP substrate (Sigma) covered with foil for 10 minutes. 
Samples were then washed in PBST and bleached for 15 minutes in bleaching 
solution (5% formamide, 10% H2O2 in PBS). The samples were then stored in PBS 
at 4 ºC until imaging. Pictures and analysis were processed using a Zeiss 
LumarV12 microscope equipped with an AxioCamera and the AxioVision 
software. 
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5.4 Results 
 
First of all, the level of expression of RNaseT2 had to be defined in melanoma. 
This was first assessed in vitro using various human melanoma cell lines, some 
with highly metastatic properties and some less invasive, and expression levels 
were compared to the HEM-nMp cell line of normal melanocytes. The result 
showed no difference at the protein expression level between all the melanoma cell 
lines used and the normal melanocytes (Figure 5.2). 
The expression of rnaset2 was then measured in vivo using the zebrafish melanoma 
model over-expressing V12Ras in melanocytes (Michailidou, Jones et al. 2009). 
Four tumours and three skin samples from the adult V12Ras transgenic line, along 
with skin from three adult wild types were dissected to extract RNA and produce 
corresponding cDNA. The level of expression of rnaset2 was assessed by RT-PCR 
and showed an up-regulation in the tumour and skin samples taken from the 
V12Ras animals compared to the wild type skin samples (Figure 5.2 B). 
 
Next, rnaset2 mutants were crossed to the V12Ras line to produce heterozygote 
animals. This progeny was then in-crossed and genotyped in order to create a 
V12Ras transgenic line in wild type and in rnaset2 mutant background. The 
genotype was done using the extra Mse1 restriction site created by the TA 
mutation present in rnaset2 mutants (Figure 5.3 A). Flanking primers of the 
mutation were designed in order to create a fragment by nested PCR that could be 
digested by the MseI restriction enzyme. The digest could then reveal a shorter 
fragment of 316bp in null mutant compared to a bigger fragment of 356bp in wild 
type, heterozygote having both of the copies (Figure 5.3 B-C). The fish were then 
grouped by genotype and analysed. A normal mendelian genotype ration was 
observed; 25% null, 25% wild type and 50% heterozygote for the mutation (Figure 
5.3 D). 
To look at the role of rnaset2 in tumourigenesis, tumours were counted and 
measured from mutants and wild types crossed to the V12Ras line. The frequency 
                                                                                 Chapter V: RNaseT2 and Cancer 
 
 118 
of tumour apparition was measured every month for over a year and showed no 
significant difference between mutant and wild type V12Ras transgenic lines 
(Figure 5.4 A). The size of the tumour was also measured with a digital calliper and 
showed no difference (Figure 5.4 B). 
 
Finally, to verify the role of rnaset2 in angiogenesis, mutant and wild type 70hpf 
embryos were stained with the alkaline phosphatase assay to visualise blood 
vessels of their intestinal basket (Figure 5.5 A). The area of the basket was 
measured (Figure 5.5 B), the extensions were counted and their length measured 
(Figure 5.5 C). The comparison between wild type and mutant embryos for the area 
of the basket, the number of extension and their length showed no significant 
difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 Chapter V: RNaseT2 and Cancer 
 
 119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: RNaseT2 is not down regulated in melanoma.  Western blot analysis 
of melanoma cell lines compared to normal melanocytes HEM-nMP reveals little 
variation in RNASET2 expression (A). In vivo analysis of rnaset2 expression in 
V12Ras tumour and skin samples showed an up-regulation of the expression at the 
message level by RT-PCR compared to WT skin samples (B). 
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Figure 5.3: Genotyping: The TA conversion in rnaset2 deficient mutant 
introduced an extra MseI restriction site (A). Primers designed around the mutation 
amplified a fragment that, once digested with MseI, was shorter in the mutant than 
in the wild type (B), which could be visualised by running the digest on a gel (C). 
A normal Mendelian ratio was observed in offspring, as approximately 50% were 
heterozygote, 25% were null and 25% wild type for the mutation (D). 
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Figure 5.4: rnaset2 does not regulate tumourigenesis in melanoma. 
Analysis of the tumour formation frequency was performed for more than a year by 
monitoring tumour appearance monthly. There was no significant difference 
between wild type (n=49) and rnaset2 mutant (n=40) animals. The Kaplan Meier 
curves were analysed by a log-rank test and gave the following results: χ2=1.557, 
df=1 and p=0.2122 (A). Tumour size was measured every week for 5 weeks. The 
analysis did not yield any statistical difference in growth between mutant and wild 
type cohorts (n=8 for both). A T-Test was performed for the last 2 points of the 
curve and generated a p value of 0.780, indicating no statically significant 
differences (B). 
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Figure 5.5: rnaset2 does not regulate angiogenesis. 70hpf embryos were fixed 
and stained for endogenous alkaline phosphatase activity to visualise blood vessels 
of the intestinal basket (A). The area of the basket was measured (red line), along 
with the number of blood vessel extensions and the cumulative length of the 
individual elements (red writing)(B-C). A T-test identified no significant difference 
between mutant (n=20) and wild type (n=20) in the area of the basket 
(p=0.627)(D), the number of extensions (p=0.681)(E) nor their length 
(p=0.083)(F). 
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5.5 Discussion 
It was demonstrated that the RNaseT2 family was not down regulated in human 
melanoma cell lines and zebrafish melanoma (Figure 5.2). These results suggest 
that RNAseT2 does not play an essential role in melanoma. Moreover, this chapter 
also showed that rnaset2 is not essential to promote neither tumourigenesis nor 
angiogenesis in zebrafish. Indeed, the absence of rnaset2 did not increase the 
frequency of tumours nor their size in a melanoma model, and did not promote 
angiogenesis. Therefore, previous reported studies claiming that RNASET2 might 
be a tumour suppressor gene (Acquati, Morelli et al. 2001; Acquati, Possati et al. 
2005) can be strongly refuted by our results. Moreover, other studies attempting to 
identify the tumour suppressor gene located at the 6q27 region deleted in ovarian 
cancer cell lines have failed to reproduce the growth suppressive effects originally 
reported for RNASET2 (Liu, Dodds et al. 2002; Bignone, Lee et al. 2007). 
RNASET2 was considered as a candidate, as suggested by the gene location 
between the 2 critical markers of that region (Acquati, Morelli et al. 2001; Liu, 
Emilion et al. 2002). Rather, the p90 ribosomal S6 kinase-3 gene coding for 
RPS6KA2 has been advanced as a better candidate. This gene was mutated in some 
ovarian cell lines, and re-expression of the gene inhibited cell growth, suggesting 
that RPS6KA2 was the tumour suppressor gene lost in ovarian cancer (Bignone, 
Lee et al. 2007). 
 
The results described in this chapter do not however nullify the hypothesis that 
RNaseT2 proteins might be employed as anti-tumourigenic drugs, indeed 
ribonucleases have been studied as anticancer agents for generations. Various 
ribonucleases belonging to the pancreatic-type ribonuclease superfamily, with 
sequence and structure homologous to the bovine pancreatic ribonuclease A 
(RNase A), have been studied and described as anti-cancer agents with significant 
selectivity for cancer cells (Beintema and Kleineidam 1998). Bovine seminal 
ribonuclease (BS-RNase) belongs to the superfamily of pancreatic RNAses A and 
showed antitumour properties in vitro and in vivo on epithelial tumor-derived cells 
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and on metastatic Lewis lung carcinoma bearing mice (Laccetti, Portella et al. 
1992; Laccetti, Spalletti-Cernia et al. 1994). 
Another homologue of RNase A, Onconase, isolated from embryos of the leopard 
frog R. pipiens was described to be 10-30 fold more cytotoxic than BS-RNase 
(Ardelt, Mikulski et al. 1991; Matousek, Soucek et al. 2003). Onconase antitumor 
properties have also been demonstrated in vitro against different carcinomas cell 
lines, yielding a G1 phase cell-cycle arrest and a decrease in RNA content 
(Darzynkiewicz, Carter et al. 1988). Twenty years later, after numerous in vitro 
and in vivo studies on mice bearing Madison carcinoma, Onconase was shown to 
be therapeutic for patients with malignant mesothelioma and is now being further 
evaluated in a phase III clinical trial, used in combination with Doxorubicin or as 
monotherapy (Mikulski, Ardelt et al. 1990; Pavlakis and Vogelzang 2006).  
More recently, Amphinase was also found in R. pipiens as another homologue of 
RNAse A and showed similar in vitro anticancer properties to Onconase (Singh, 
Ardelt et al. 2007).  
A bacterial ribonuclease belonging to the RNase T1 family, called Binase, was also 
found to be cytotoxic (Ilinskaya, Decker et al. 2001; Ilinskaya, Zelenikhin et al. 
2007). However, Binase did not show any selectivity towards cancer cells 
(Ilinskaya, Decker et al. 2001). 
 
The mechanism of action of antitumorigenic RNases is unclear, but a molecular 
model can be proposed based on many reviews (Benito, Ribo et al. 2005; Ardelt, 
Shogen et al. 2008; Ardelt, Ardelt et al. 2009). Cytotoxic RNases interact with the 
cell membrane and are endocytosed by the cell. Electrostatic forces were proposed 
to be at the origin of the preferential sensitivity to cancer cells (Johnson, Chao et al. 
2007). The cytotoxic RNases from the RNase A family are strongly cationic 
molecules, the opposite charge of cancer cells, and can be efficiently attached to 
the negatively charged membrane of cancer cells (Marquez, Nilsson et al. 2004). 
Once translocated into the cytosol, RNases degrade cytosolic RNA, triggering 
apoptosis. This mechanism however still needs to be confirmed. 
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Available zebrafish cancer models were discussed in the introduction along with 
the advantage of possessing a mutant line for a given gene. The combination of the 
V12Ras line with the rnaset2 mutant offers a unique model to study the role of 
rnaset2 in cancer. An autochthonous tumor model combined with a mutant offers a 
better evaluation of the role of a given gene in tumorigenesis compared to 
xenograft assays and over-expression, antisense or recombinant protein 
approaches. Future work using this unique model could be performed to study the 
potential therapeutic effect of RNaseT2 on cancer. 
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Chapter VI: General discussion 
 
 
“Classic” lysosomal storage disorders follow a chronology in which a clinician first 
describes the disease with its symptoms years before its molecular basis is 
discovered. The identification of the substance that accumulates is generally 
followed by the discovery of the defective enzyme, and only then a relevant 
treatment can be developed (Futerman and van Meer 2004). 
The results presented in this doctorate project combined with the literature provide 
an accelerated chronology of events allowing a fast molecular characterisation of 
the symptoms first discovered by Henneke et al (Henneke, Preuss et al. 2005; 
Henneke, Diekmann et al. 2009)(Figure 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Chronology of the RNASET2 deficient leukoencephalopathy 
disease, showing the history of the disease with the critical dates for the relevant 
discoveries and future studies. 
Apr 2005 Jul 2009 June 2010 …
Description of a novel 
disease by Marco 
Henneke and Jutta
Gärtner (Henneke, 
2005).
Discovery of RNASET2 
as the defective enzyme
in patients (Henneke, 
2009).
Identification of the nature of the 
disease using zebrafish as an 
animal model. Rnaset2 deficient 
zebrafish suffer from an LSD, 
accumulating undigested rRNA
in neurons and display similar 
symptoms previously described in 
RNASET2 deficient children 
(present study). 
Further studies on 
disease mechanism and 
development of future 
potential treatment.
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The work presented herein describes and characterises deficiency of rnaset2 in 
zebrafish. RNASET2 was presented as a lysosomal hydrolase, but its function was 
still unknown (Campomenosi, Salis et al. 2006). In this study, a zebrafish mutant 
for rnaset2 created by ENU mutagenesis provides the molecular mechanism of the 
leukoencephalopathy observed in RNASET2 deficient children. Deficiency of 
rnaset2 was shown to cause an LSD resulting in the accumulation of rRNA in 
lysosomes of neurons (Figure 4.4). This result provides a function for rnaset2 as 
the main actor to recycle bulk RNA (rRNA) in the specific process called 
ribophagy. This study also demonstrates that rnaset2 is not a tumour suppressor 
gene and does not promote angiogenesis in zebrafish. 
 
Although the results presented in this thesis do not associate the lysosomal storage 
disorder observed in rnaset2 mutant to tumourigenesis, lysosomes were shown to 
have a role in cancer. Recent work discovered new roles for some lysosomes 
proteases, such as the cathepsins, in angiogenesis, cancer cell invasion and cell 
death (Guicciardi, Leist et al. 2004). As already introduced in the general 
introduction (1.1.2.3), apoptosis can be triggered by lysosomes in cancer cells 
when the normal activation pathways are inhibited. Thus lysosomal pathways can 
be targeted by chemotherapy agents to induce apoptosis in cancer cells resistant to 
previous treatment (Kirkegaard and Jaattela 2009). Some lysosomal proteases also 
activate angiogenesis and tumour growth. In cancer cells, changes in lysosomal 
compartment by transformation can have tumourigenic effects (Mohamed and 
Sloane 2006). In the future, more molecular mechanisms are essential to 
understand the lysosomal pathways and their potential application in cancer 
therapy. 
 
The use of this zebrafish model could be extended to further characterise the 
function of the RNaseT2 family protein. Similar experiments to the rescue 
performed in Chapter II could be adapted to study the role of various domains of 
the protein. Its catalytic domains can be mutated by simple mutagenesis to create a 
catalytic dead enzyme (Acquati, Possati et al. 2005). Potential phosphorylation 
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sites and sorting signal tags common to other lysosomal hydrolases could also be 
targeted. Simple injection of these deficient proteins in one cell stage zebrafish 
embryos would help to biochemically characterise rnaset2 functions.  
 
Zebrafish rnaset2 is highly expressed in embryos and in all tissue throughout their 
adult life (Hillwig, Rizhsky et al. 2009). Moreover, RNaseT2 enzymes are the only 
ribonuclease conserved in all organisms, including bacteria, viruses, fungi, plants 
and animals (Irie 1999; Hillwig, Rizhsky et al. 2009; MacIntosh, Hillwig et al. 
2010). These data show that RNaseT2 enzymes play an important role that has 
been conserved throughout evolution. The new role for rnaset2 described in this 
study suggests that it might be conserved in all eukaryotes. The function of 
RNaseT2 in ribophagy was confirmed in plants where deficiency in RNS2, the 
lysosomal plant homologue of RNASET2, dramatically increased the half-life of 
rRNA (M. Hillwig and G. MacIntosh unpublished). All together, these data present 
RNaseT2 as a house keeping gene with the function to recycle bulk RNA (mostly 
rRNA). Deficiencies in ribophagy resulted in constitutive autophagy, confirming 
the crucial role of RNaseT2 proteins in maintaining cell homeostasis (Figure 4.5, 
and M. Hillwig and G. MacIntosh unpublished). 
 
The impaired recycling of ribosomes in rnaset2 zebrafish mutant might offer a 
unique tool to study the origin of the autophagosome membrane. Indeed very little 
information is available on this subject. It was recently demonstrated that the 
autophagosome membrane originated from the endoplasmic reticulum (ER) by 
showing interconnection of the autophagosome membrane with the ER (Hayashi-
Nishino, Fujita et al. 2009; Hayashi-Nishino, Fujita et al. 2010). Ribosomes are 
attached to the ER membrane and further study of the ribophagy process could lead 
to the potential confirmation of the ER origin of the autophagosome membrane.   
These results could be confirmed by studying the composition of the membrane of 
the enlarged lysosomes present in the rnaset2 mutant. 
 
By unknown mechanisms, this accumulation of undigested substrates triggered 
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cytotoxicity that resulted in axonal damage and increased inflammation within 
white matter lesions in the zebrafish brain (Figure 4.6, 4.7, and 4.9). In future, 
rnaset2 zebrafish mutant will be a central platform to study the molecular 
mechanism resulting in the symptoms observed in the LSD due to deficiency of 
this protein. As already introduced in 4.5, microglia play a role in the inflammatory 
response and are highly present in the white matter lesions in the brain of rnaset2 
zebrafish mutants (Figure 4.9). The optical clarity of zebrafish allowing live 
imaging in embryos, alongside the availability of various transgenic lines in which 
GFP is expressed in microglia and different dyes that can be used to specifically 
tag lysosomes (eg: CD-63 mRNA, DQ-BSA Invitrogen), make zebrafish a unique 
model to further study the leukoencephalopathy discovered in RNASET2 deficient 
children. To determine the involvement of microglia in the disease mechanism, the 
microglia transgenic line pU1-Gal4-UAS-eGFP (U. Wolke, W. Driever and M. 
Prinz unpublished) in the rnaset2 background can be used to analyse microglia 
density and motility (Fuhrmann, Bittner et al. 2010), microglia morphology, 
distribution in different brain regions and alterations in phagocytosis behaviour 
(Peri and Nusslein-Volhard 2008). 
 
Zebrafish can also be used as a pharmacological tool to develop a potential future 
treatment. Indeed, zebrafish is already extensively used in drug discovery due to 
their comparable ADME enzymes with humans, their ability to live in a 96-well 
plate and to absorb drug directly from the water and their tolerance of DMSO 
(Goldsmith 2004). A small molecule screen could be performed without much cost 
in this model: a decent library of FDA approved compounds can be purchased for 
only a few thousand pounds. The early manifestation of the phenotype will allow 
zebrafish embryos to be treated in a 96 well plate and AO will be used as a tool to 
visualise any differences in phenotype after drug treatment. The flow cytometry 
assay developed in this study to quantify changes in fluorescence will be used to 
validate therapeutic targets in this system. 
The use of MRI to identify white matter lesions can also be performed on living 
fish (Kabli, Alia et al. 2006). This technique would allow longitudinal study in 
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adult to assess the disease course, as well as the effect of therapeutic drugs. 
 
In conclusion, this study presents a zebrafish mutant for the rnaset2 gene providing 
a model for a form of leukoencephalopathy in man. This mutant can serve as a 
preclinical animal model for further elucidating the disease pathophysiology 
linking RNA accumulation with axonal degeneration and white matter alterations. 
Moreover, this mutant offers the only animal model available to study the function 
of rnaset2 in cancer and shows no significant role in melanoma tumourigenesis and 
angiogenesis. Possessing this mutant will serve as an ultimate link between the 
human disease and the identification of factors leading to cytotoxicity. 
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Appendix, Figure 1: pGEM-T vector map 
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Chromosome Position (cM) Z marker  
   1 25.6 6775 
1 33.7 14683 
1 61.4 6802 
1 77.7 22347 
2 24.8 22747 
2 38.3 13620 
2 58.2 13521 
2 81.5 6818 
3 30.5 1185 
3 53.7 8406 
3 64.9 10934 
3 100.6 7486 
4 9.3 23182 
4 26 20533 
4 56.6 9247 
4 79.2 15751 
5 17.1 11496 
5 28.2 8921 
5 60.9 5538 
5 83.1 11632 
6 12 9254 
6 21.7 11466 
6 53.6 11919 
6 72.6 7666 
7 25.1 1206 
7 52.2 1059 
Chromosome Position (cM) Z marker  
7 70.5 1239 
7 98.3 8218 
8 30.5 7819 
8 49.3 22270 
8 65.8 13984 
8 100.7 8703 
9 5.9 1830 
9 23.6 6268 
9 64.2 14949 
9 70 10789 
10 27.9 8146 
10 53.3 6390 
10 78.3 14193 
10 92.5 7388 
11 24 6909 
11 40.7 4190 
11 56 8032 
11 65.7 10727 
12 22.3 6920 
12 41 22103 
12 62 10225 
12 78.7 1312 
13 4.7 4076 
13 25.2 9564 
13 51.5 17223 
13 76 55309 
14 10.4 25920 
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Chromosome Position(cM) Z marker  
14 34.6 5435 
14 60 9366 
14 91.9 11837 
15 15.4 6712 
15 49.3 6895 
15 67 13230 
15 98.2 5223 
16 11.4 13202 
16 34.9 6921 
16 43.4 3104 
16 63 15453 
17 8.6 9179 
17 36.2 19625 
17 66 9692 
17 87.1 24276 
18 7.3 11685 
18 21.5 11944 
18 62 9941 
18 78.2 59737 
19 13 6192 
19 39.4 20773 
19 59 9384 
19 81.5 1651 
20 21.2 9708 
 
 
 
 
 
 
 
 
 
 
 
Chromosome Position (cM) Z marker  
20 67.5 21170 
20 75.6 4394 
20 92.3 7171 
21 27.7 15891 
21 46 4425 
21 71.1 52940 
21 116.7 1497 
22 17.2 3093 
22 30.3 7125 
22 55.8 9084 
22 68.6 25795 
23 17 4003 
23 36.6 5141 
23 46 1665 
23 61.4 24085 
24 16.6 5413 
24 42.9 9321 
24 53.5 9603 
24 76.9 8209 
25 28.1 23933 
25 38 15480 
25 40.3 8224 
25 54.4 22028 
Appendix, Figure 2: Z-Markers positions used for the low resolution mapping 
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Appendix, Figure 3: Schematic of the mutation segregation during meiosis. The 
black squares show the location of the mutation. Note that the mutation always 
conserves the same genetic background due to its proximity during meiosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix, Figure 4: Ef1α_intron_cherry map 
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Appendix, Figure 5: pcGlobin 2 map [taken from (Ro, Soun et al. 2004)] 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix, Figure 6: In situ sense and antisense probe. Note the difference of 
signal between sense and antisense probe and the autofluorescence of the eye 
lenses. 
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Appendix, Figure 7: RT-PCR on cDNA from HEK 293 cells to evaluate the 
efficiency of RNASET2 knock down by miRNA1 and miRNA2. The expression of 
RNASET2 was dramatically reduced 72 hours after transfection of miRNA2, 
unlike miRNA1 which had no effect on RNASET2 expression and was therefore 
used as a control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix, Figure 8: Anatomy analysis between mutants and wild types. 3 months 
old animals were measured and weighted and showed no differences between 
mutant and wild type. 
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Appendix, Figure 9: In situ hybridization using different brain markers. The 
probes fgfr3, hoxb1a and pax2 showed no difference in brain morphology between 
wild type and mutant embryos. 
wt mutant
fgfr3
pax2
hoxb1a
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